

CITATION REPORT

List of articles citing

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

**DOI: 10.1016/s0140-6736(17)32802-7
Lancet, The, 2018, 391, 1357-1366.**

Source: <https://exaly.com/paper-pdf/68757250/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1704	More data, more answers: picking the optimal antidepressant. <i>Lancet, The</i> , 2018 , 391, 1333-1334	40	5
1703	Anxiety About Antidepressants. 2018 , 175, 500-501		2
1702	Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. 2018 , 175, 873-886		78
1701	Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. 2018 , 137, 450-458		29
1700	Antidepressants might work for people with major depression: where do we go from here?. 2018 , 5, 461-463		12
1699	Commentary: Randomized controlled trials in autism spectrum disorder: state of the field and challenges for the future. 2018 , 59, 457-459		5
1698	Neue Studien zum Thema "Depression" 2018 , 19, 20-21		
1697	Beating "the black dog" 2018 , 2018, 14-16		
1696	Are the effects of blood pressure lowering treatment diminishing?: meta-regression analyses. 2018 , 24, 16		
1695	Bibliography: Psychotherapy: Access to Effective Treatments. 2018 , 16, 415-416		
1694	Comparison of 21 Antidepressants. 2018 , 16, 4s		
1693	Long, Hot Showers and Cannabinoid Hyperemesis Syndrome. 2018 , 16, 4s-5s		
1692	Wirkung von Citalopram und Paroxetin nicht durch Nebenwirkungen erklärbar. 2018 , 20, 10-10		
1691	Antidepressants work better than placebo, meta-analysis confirms. 2018 , 24, 16		
1690	Diagnostik und Therapie der unipolaren Depression. 2018 , 15, 9-21		
1689	Statistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove That the Drugs Work: Effect Size and Method Bias Matter!. 2018 , 9, 517		38
1688	Author's reply. 2018 , 32, 1150		

1687	Taking Our Meds Faithfully? Christian Engagements with Psychiatric Medication. 2018 , 24, 216-223		
1686	Physiology on television. 2018 , 103, 1292-1293		0
1685	Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects. 2018 , 13, 176-186		65
1684	Unbalanced risk-benefit analysis of ADHD drugs - Authors' reply. 2018 , 5, 871-873		2
1683	Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study. 2018 , 8, e023222		8
1682	Psychiatry might need some psychedelic therapy. 2018 , 30, 285-290		5
1681	Differenzielle Therapieentscheidung bei unipolaren Depressionen. 2018 , 19, 24-30		
1680	The Challenges of Improving Treatments for Depression. 2018 , 320, 2529-2530		39
1679	Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders - Results from a double-blind, randomized and placebo-controlled clinical trial. 2018 , 107, 48-56		36
1678	Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression. 2018 , 9, 424		12
1677	Network meta-analysis of antidepressants - Authors' reply. <i>Lancet, The</i> , 2018 , 392, 1012-1013	40	3
1676	Network meta-analysis of antidepressants. <i>Lancet, The</i> , 2018 , 392, 1011	40	7
1675	Network meta-analysis of antidepressants. <i>Lancet, The</i> , 2018 , 392, 1011-1012	40	3
1674	Network meta-analysis of antidepressants. <i>Lancet, The</i> , 2018 , 392, 1011	40	4
1673	Network meta-analysis of antidepressants. <i>Lancet, The</i> , 2018 , 392, 1010	40	8
1672	Network meta-analysis of antidepressants. <i>Lancet, The</i> , 2018 , 392, 1010-1011	40	6
1671	Guest Editorial. 2018 , 32, 95-101		0
1670	Five Interpersonal Factors Are Predictive of the Response to Treatment of Major Depression With Antidepressants in Primary Care. 2018 , 9, 416		8

1669	Examining the 'psychopharmacology revolution' (1950-1980) through the advertising of psychoactive drugs in the British Medical Journal. 2018 , 32, 1056-1066		4
1668	Language bias and comprehensive meta-analysis of folate for unipolar depression. 2018 , 32, 1150		
1667	Depression. <i>Lancet, The</i> , 2018 , 392, 2299-2312	40	783
1666	Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline. 2018 , 14, 2473-2484		4
1665	Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. 2018 , 1102-1103, 135-142		1
1664	syn-Selective alkylarylation of terminal alkynes via the combination of photoredox and nickel catalysis. 2018 , 9, 4543		71
1663	Neural mechanisms of emotion regulation and their role in endocrine and immune functioning: A review with implications for treatment of affective disorders. 2018 , 95, 508-514		16
1662	Internet-Based Cognitive-Behavioral Therapy in the Treatment of Depression. 2018 , 16, 393-394		3
1661	Authors' Response to Brailon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring". 2018 , 41, 1417-1418		
1660	Study Protocol for a Randomized Double Blind, Placebo Controlled Trial Exploring the Effectiveness of a Micronutrient Formula in Improving Symptoms of Anxiety and Depression. 2018 , 5,		
1659	Recent Findings of the Comparative Efficacy and Tolerability of Antidepressants for Major Depressive Disorder: Do We Now Know What to Prescribe?. 2018 , 32, 807-811		1
1658	How promising is neuroactive steroid drug discovery?. 2018 , 13, 993-995		3
1657	Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant. 2018 , 26, 537-540		4
1656	The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. 2018 , 94, 219-237		71
1655	Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?. 2018 , 268, 621-623		4
1654	Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have. 2018 , 30, 266-274		1
1653	What is the threshold for a clinical minimally important drug effect?. 2018 ,		5
1652	Lässt sich ein sinnvolles Ranking von Antidepressiva erstellen?. 2018 , 20, 11-14		

1651	Antidepressant induced weight gain. 2018 , 361, k2151	1
1650	What Is New about New Antidepressants?. 2018 , 87, 129-139	26
1649	What does the latest meta-analysis really tell us about antidepressants?. 2018 , 27, 430-432	7
1648	Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. 2018 , 17, 196-209	134
1647	Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. 2018 , 72, 306-313	19
1646	Kaleidoscope. 2018 , 212, 389-390	
1645	Weighing up the benefits of antidepressant drugs. 2018 , 29, 13-16	1
1644	Depressive symptoms predict incident chronic disease burden 10 years later: Findings from the English Longitudinal Study of Ageing (ELSA). 2018 , 113, 30-36	25
1643	Preferences for Depression Treatment Including Internet-Based Interventions: Results From a Large Sample of Primary Care Patients. 2018 , 9, 181	28
1642	Using Affective Cognition to Enhance Precision Psychiatry. 2018 , 9, 288	2
1641	The benefits of antidepressants: news or fake news?. 2018 , 213, 454-455	9
1640	A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)-The Case of Herbal Medicinal Products Containing St. John's Wort Extracts (SJW). 2018 , 10,	3
1639	There is no news. 2018 , 56, 61	
1638	Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN:)D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. 2018 , 16, 103	29
1637	Ideology over evidence?. 2018 , 42, 130-131	2
1636	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. 2018 , 28, 970-979	14
1635	The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis. 2018 , 27, 537-542	17
1634	The Electrochemical Brain: Lessons From The Bell Jar and Interventional Psychiatry. 2018 , 84, e23-e24	1

1633	Making sense of the evolving nature of depression narratives and their inherent conflicts. 2018 , 11, 144-160	3
1632	The role of oxidative stress in anxiety disorder: cause or consequence?. 2018 , 52, 737-750	52
1631	Kaleidoscope. 2018 , 212, 326-327	
1630	Editorial Perspective: Antidepressants and the depressed adolescent. 2018 , 23, 137-140	
1629	Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. 2018 , 18, 165	19
1628	Anatomically Defined and Functionally Distinct Dorsal Raphe Serotonin Sub-systems. 2018 , 175, 472-487.e20	143
1627	Dropouts in an Antidepressant Trial: How Do They Fare Afterwards?. 2018 , 87, 380-382	1
1626	A systematic review of acupuncture and Chinese herbal medicine for postpartum depression. 2018 , 33, 85-92	12
1625	The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. 2018 , 241, 484-491	59
1624	Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis. 2018 , 47, 1454-1464	22
1623	Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder. 2018 , 238, 122-128	9
1622	Essential medicines and the challenges in the Evidence-Based Manifesto. 2018 , 23, 123-124	1
1621	Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. 2019 , 214, 4-10	13
1620	Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. 2019 , 49, 1118-1127	72
1619	Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects. 2019 , 70, 599-625	96
1618	Methodological concerns with network meta-analysis on drugs for attention deficit hyperactivity disorder. 2019 , 28, 145-146	1
1617	Studien-Highlights für die Praxis aufbereitet. 2019 , 21, 50-54	
1616	Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. 2019 , 20, 427-448	51

1615 Reconfiguring Recovery Beyond Linearity. **2019**, 61-106

1614 Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. **2019**, 118, 21-30 15

1613 Practical liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of amitriptyline, nortriptyline and their hydroxy metabolites in human serum. **2019**, 33, e4679 4

1612 The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. **2019**, 6, 675-712 411

1611 Mechanisms and treatment of late-life depression. **2019**, 9, 188 125

1610 Assessing low mood during pregnancy. **2019**, 366, l4584 1

1609 Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. **2019**, 8, 535-547 11

1608 Diabetes Update 2019. **2019**, 15, 376-381

1607 Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. **2019**, 6, 753-765 15

1606 Does rTMS on brain areas of mirror neurons lead to higher improvements on symptom severity and empathy compared to the rTMS standard procedure? - Results from a double-blind interventional study in individuals with major depressive disorders. **2019**, 257, 527-535 4

1605 Polymorphisms in the BDNF and BDNFOS genes are associated with hypothalamus-pituitary axis regulation in major depression. **2019**, 95, 109686 14

1604 Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3). **2019**, 15, 795-808 9

1603 Depression, antidepressants and the risk of cardiovascular events and death in older men. **2019**, 128, 4-9 9

1602 Madness and Genetic Determinism. **2019**,

1601 Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet, The*, **2019**, 394, 939-951 40 504

1600 Placebo mechanisms in depression: An experimental investigation of the impact of expectations on sadness in female participants. **2019**, 256, 658-667 9

1599 Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. **2019**, 29, 1003-1022 24

1598 Serotonergic-like profile of 4-propyl-2H-benzo[h]-chromen-2-one (FCS-304) in mice and rats. **2019**, 26, 17-22

- 1597 What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?. **2019**, 9, 2045-2053 19855206 8
- 1596 Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study. **2020**, 21, 185-194 9
- 1595 Can Machine Learning Approaches Lead Toward Personalized Cognitive Training?. **2019**, 13, 64 12
- 1594 Prevalence and predictors of probable depression in prostate cancer survivors. **2019**, 125, 3418-3427 21
- 1593 A perspective: from the serotonin hypothesis to cognitive neuropsychological approaches. **2019**, 95-104 2
- 1592 Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. **2019**, 9, e024886 55
- 1591 Barriers and facilitators to community-based psycho-oncology services: A qualitative study of health professionals' attitudes to the feasibility and acceptability of a shared care model. **2019**, 28, 1862-1870 7
- 1590 Low mood and depressive symptoms during perimenopause - Should General Practitioners prescribe hormone replacement therapy or antidepressants as the first-line treatment?. **2019**, 25, 124-130 2
- 1589 Determination of Antidepressants and Antipsychotics in Dried Blood Spots (DBSs) Collected from Post-Mortem Samples and Evaluation of the Stability over a Three-Month Period. **2019**, 24, 19
- 1588 The burden of suicidal ideation across Europe: a cross-sectional survey in five countries. **2019**, 15, 2257-2271 8
- 1587 Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences. **2019**, 39, 998-1009 4
- 1586 Outcomes help map out evidence in an uncertain terrain, but they are relative. **2019**, 18, 293-295 1
- 1585 US Food and Drug Administration approval of esketamine and brexanolone. **2019**, 6, 975-977 33
- 1584 Imipramin oder Antidepressiva-Kombination?. **2019**, 21, 24-24
- 1583 Targets and outcomes of psychotherapies for mental disorders: an overview. **2019**, 18, 276-285 61
- 1582 Targets and outcomes of psychological interventions: implications for guidelines and policy. **2019**, 18, 295-296 2
- 1581 The all-encompassing perspective of the mental health care patient. **2019**, 18, 296-297 3
- 1580 Incidence of suicidal behaviour and violent crime following antidepressant medication: a Danish cohort study. **2019**, 140, 522-531 7

1579 Managing depression in the primary care setting. **2019**, 1, 388-392

1578 Antidepressant Withdrawal and Rebound Phenomena. **2019**, 116, 355-361

23

1577 A Stage-Based Approach to Therapy in Parkinson's Disease. **2019**, 9,

28

1576 Strategies for antidepressants extraction from biological specimens using nanomaterials for analytical purposes: A review. **2019**, 150, 104193

10

1575 Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update. **2019**, 18, 949-963

15

1574 Trim the fat: the role of omega-3 fatty acids in psychopharmacology. **2019**, 9, 2045125319869791

10

1573 Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines. **2019**, 19, 265

5

1572 International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. **2019**, 88, 263-273

66

1571 Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies. **2019**, 11,

5

1570 One step closer to personalised prescribing of antidepressants: using real-world data together with patients and clinicians' preferences. **2019**, 22, 91-92

9

1569 Ketamine metabolite pilot study in a suicidal depression trial. **2019**, 117, 129-134

14

1568 Toward a paradigm shift in treatment and research of mental disorders. **2019**, 49, 2111-2117

21

1567 Efficacy of a standardised saffron extract (affron[®]) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study. **2019**, 33, 1415-1427

16

1566 Pharmacokinetic considerations for current state-of-the-art antidepressants. **2019**, 15, 831-847

11

1565 Antidepressant-like effect induced by P2X7 receptor blockade in FSL rats is associated with BDNF signalling activation. **2019**, 33, 1436-1446

10

1564 Treatments for depression: Side-effects, adverse events and health risks. **2019**, 259, 38-39

1

1563 The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. **2019**, 6, 903-914

52

1562 Examining the antidepressant scattergun approach. **2019**, 6, 878-879

2

1561	Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites. 2019 , 15, 2655-2661	3
1560	[Rheumatism and the mind-A mini review]. 2019 , 48, 957-962	4
1559	The future of rodent models in depression research. 2019 , 20, 686-701	92
1558	Pharmacological treatments for generalised anxiety disorder - Authors' reply. <i>Lancet, The</i> , 2019 , 394, 1230	40
1557	Pharmacokinetics and Safety of Vortioxetine in the Chinese Population. 2019 , 36, 3134-3146	5
1556	Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. 2019 , 76, 1241-1255	72
1555	Iron overload as a high risk factor for microgravity-induced bone loss. 2019 , 164, 407-414	5
1554	Effect of probiotics on depressive symptoms: A meta-analysis of human studies. 2019 , 282, 112568	37
1553	Orexinergic modulation of serotonin neurons in the dorsal raphe of a diurnal rodent, <i>Arvicantthis niloticus</i> . 2019 , 116, 104584	7
1552	Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. 2019 , 6, 935-950	35
1551	Optimal dosing of antidepressant drugs - Authors' reply. 2019 , 6, 806-807	1
1550	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. 2019 , 3, 1319-1331	15
1549	Basic symptoms in offspring of parents with mood and psychotic disorders. 2019 , 5, e54	7
1548	The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Unipolar Nonpsychotic Depression. 2019 , 27, 33-52	9
1547	The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. 2019 , 6, 95-110	22
1546	Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. <i>Lancet, The</i> , 2019 , 393, 768-777	40 114
1545	The Meaning and Influence of Time-Related Dropout Dynamics in Antidepressant Studies: Reassessing Current Approaches. 2019 , 88, 37-38	3
1544	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. 2019 , 215, 494-501	6

1543	Ethnopsychopharmacology study of patients' beliefs regarding concerns about and necessity of taking psychiatric medications. 2019 , 34, e2688	3
1542	Challenging the promotion of antidepressants for nonsevere depression. 2019 , 139, 294-295	10
1541	The antidepressant impact of minocycline in rodents: A systematic review and meta-analysis. 2019 , 9, 261	11
1540	Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. 2019 , 130, 65-77	30
1539	Depression and Antidepressants as Potential Risk Factors in Dementia: A Systematic Review and Meta-analysis of 18 Longitudinal Studies. 2019 , 20, 279-286.e1	18
1538	Antidepressive Effects of Taraxacum Officinale in a Mouse Model of Depression Are Due to Inhibition of Corticosterone Levels and Modulation of Mitogen-Activated Protein Kinase Phosphatase-1 (Mkp-1) and Brain-Derived Neurotrophic Factor (Bdnf) Expression. 2019 , 25, 389-394	5
1537	Evolving Issues in the Treatment of Depression. 2019 , 321, 2401-2402	5
1536	C.05.01 Traditional efficacy of antidepressants: Does it reflect your long-term treatment goals?. 2019 , 29, S621-S622	
1535	Placebo Effect in the Treatment of Depression and Anxiety. 2019 , 10, 407	60
1534	Regulatory sciences and translational pharmacogenetics: amitriptyline as a case in point. 2019 , 34,	
1533	Effects of continuous positive airway pressure on depression and anxiety symptoms in patients with obstructive sleep apnoea: results from the sleep apnoea cardiovascular Endpoint randomised trial and meta-analysis. 2019 , 11, 89-96	24
1532	Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain. 2019 , 44, 1706-1713	3
1531	Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: A Re-Analysis of the FDA Database. 2019 , 88, 247-248	29
1530	The impact of selective serotonin reuptake inhibitors on the risk of intracranial haemorrhage: A systematic review and meta-analysis. 2019 , 4, 144-152	7
1529	Selective serotonin reuptake inhibitors are still harmful and ineffective. Responses to the comments by Hieronymus. 2019 , 31, 276-284	1
1528	Resolving the paradox of increased mental health expenditure and stable prevalence. 2019 , 53, 844-850	12
1527	Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis. 2019 , 16,	20
1526	A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpReSSion): study protocol for a randomised controlled trial. 2019 , 20, 319	7

1525	Embarking on antidepressant response prediction using brain perfusion estimation. 2019 , 10, 4-5	1
1524	Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. 2019 ,	33
1523	The Relationship Between Serum Concentration of Vitamin D, Total Intracranial Volume, and Severity of Depressive Symptoms in Patients With Major Depressive Disorder. 2019 , 10, 322	11
1522	Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial. 2019 , 10, 1234	53
1521	Late stage Pd-catalyzed C-H bond functionalization: A powerful tool for the one step access to arylated Cyproheptadine and cyclobenzaprine derivatives. 2019 , 129, 105716	0
1520	Is Sertraline a Good Pharmacological Strategy to Control Anger? Results of a Systematic Review. 2019 , 9,	7
1519	Depression in the Primary Care Setting. Reply. 2019 , 380, 2279-2280	4
1518	Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. 2019 , 6, 601-609	99
1517	Which antidepressant doses are optimal?. 2019 , 6, 552-554	2
1516	Adaptive mechanisms following antidepressant drugs: Focus on serotonin 5-HT receptors. 2019 , 71, 994-1000	10
1515	Pre-clinical investigations of Ecaboline alkaloids as antidepressant agents: A systematic review. 2019 , 137, 104196	17
1514	Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. 2019 , 140, 116-125	10
1513	Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. 2019 , 9, e027574	15
1512	Have Treatment Studies of Depression Become Even Less Generalizable? Applying the Inclusion and Exclusion Criteria in Placebo-Controlled Antidepressant Efficacy Trials Published over 20 Years to a Clinical Sample. 2019 , 88, 165-170	18
1511	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. 2019 , 176, 428-438	282
1510	Depressive disorders: Treatment failures and poor prognosis over the last 50 years. 2019 , 7, e00472	32
1509	The Challenge of Treating Depression in Dementia. 2019 , 27, 932-933	
1508	Sudden Unexpected Death in Epilepsy: Mechanisms, Risk Factors and the Role of the Nurse. 2019 , 15, 64-72	1

1507	Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport. 2019 , 569, 141-145	89
1506	Power behind the throne: A clinical trial simulation study evaluating the impact of controllable design factors on the power of antidepressant trials. 2019 , 28, e1779	4
1505	Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis. 2019 , 22, 61-66	9
1504	Depression in Maltreated Children and Adolescents. 2019 , 28, 289-302	13
1503	Targeting opioid dysregulation in depression for the development of novel therapeutics. 2019 , 201, 51-76	37
1502	'Effective' at What? On Effective Intervention in Serious Mental Illness. 2019 , 27, 289-308	1
1501	The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. 2019 , 10, 294	23
1500	Machine learning and big data in psychiatry: toward clinical applications. 2019 , 55, 152-159	77
1499	Effectiveness and Acceptability of Cognitive Behavior Therapy Delivery Formats in Adults With Depression: A Network Meta-analysis. 2019 , 76, 700-707	128
1498	Pragmatic neuroscience for clinical psychiatry. 2019 , 215, 404-408	9
1497	Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. 2019 , 98, 104-116	32
1496	Development and validation of an analytical procedure to detect spatio-temporal differences in antidepressant use through a wastewater-based approach. 2019 , 200, 340-349	14
1495	The genetics of depression: successful genome-wide association studies introduce new challenges. 2019 , 9, 114	49
1494	Network meta-analysis of randomised trials of pharmacological, psychotherapeutic, exercise and collaborative care interventions for depressive symptoms in patients with coronary artery disease: hybrid systematic review of systematic reviews protocol. 2019 , 8, 71	8
1493	and genes may not be associated with venlafaxine treatment response in Chinese of Han ethnicity. 2019 , 15, 657-661	1
1492	Differential Function of Melatonin MT and MT Receptors in REM and NREM Sleep. 2019 , 10, 87	42
1491	Case 9-2019: A 62-Year-Old Man with Atrial Fibrillation, Depression, and Worsening Anxiety. 2019 , 380, 1167-1174	2
1490	The novel methoxetamine analogs N-ethylnorketamine hydrochloride (NENK), 2-MeO-N-ethylketamine hydrochloride (2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride (4-MeO-NEK) elicit rapid antidepressant effects via activation of AMPA and 5-HT receptors. 2019 , 226, 2201-2210	10

1489	Baseline serum C-reactive protein levels may predict antidepressant treatment responses in patients with major depressive disorder. 2019 , 250, 432-438	17
1488	Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. 2019 , 250, 114-122	14
1487	Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. 2019 , 139, 404-419	143
1486	Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. 2019 , 250, 419-424	15
1485	Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: A network meta-analysis. 2019 , 20, 895-905	16
1484	Organising the front line: Is there a rationale for the first-line pharmacotherapy of major depressive disorder?. 2019 , 53, 279-281	10
1483	Characteristics and trends of spontaneous reporting of therapeutic ineffectiveness in South Korea from 2000 to 2016. 2019 , 14, e0212905	5
1482	Which first-line antidepressant?. 2019 , 69, 114-115	5
1481	Fluorination of carbonyls with nucleophilic fluorine. 2019 , 11, 329-334	43
1480	It is time to investigate integrative approaches to enhance treatment outcomes for depression?. 2019 , 126, 82-94	9
1479	Pharmako- und/oder Psychotherapie bei posttraumatischer Belastungsstörung. 2019 , 64, 306-321	
1478	Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. 2019 , 199, 58-90	53
1477	Being recognised as a whole person: A qualitative study of inpatient experience in mental health. 2019 , 40, 88-96	14
1476	PC-FACS. 2019 , 57, 346-353	
1475	Pharmaco-epidemiology of antidepressant exposure in a UK cohort record-linkage study. 2019 , 33, 482-493	3
1474	Antidepressants; what's the beef?. 2019 , 31, 59-60	7
1473	Is care really shared? A systematic review of collaborative care (shared care) interventions for adult cancer patients with depression. 2019 , 19, 120	12
1472	The journey from gene knockout to clinical medicine: telotristat and sotagliflozin. 2019 , 13, 817-824	5

1471	Depression in primary care: part 2-management. 2019 , 365, l835	19
1470	Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity. 2019 , 13, 404	16
1469	Has the UK Improving Access to Psychological Therapies programme and rising antidepressant use had a public health impact?. 2019 , 6, e8-e9	7
1468	Prophylactic Ketamine Treatment Promotes Resilience to Chronic Stress and Accelerates Recovery: Correlation with Changes in Synaptic Plasticity in the CA3 Subregion of the Hippocampus. 2019 , 20,	18
1467	[Mental disorders and diabetes mellitus (Update 2019)]. 2019 , 131, 186-195	4
1466	Network meta-analysis of the efficacy and safety of antidepressants for acutely ill elderly patients with major depressive disorder. 2019 , 29, S417	
1465	Has the time come to treat depression with anti-inflammatory medication?. 2019 , 139, 401-403	2
1464	Postoperative continuation of antidepressant therapy is associated with reduced short-term weight loss following Roux-en-Y gastric bypass surgery. 2019 , 404, 621-631	5
1463	Pharmacokinetic correlates of venlafaxine: associated adverse reactions. 2019 , 269, 851-857	4
1462	Top Ten Tips Palliative Care Clinicians Should Know About Psychopharmacology. 2019 , 22, 572-579	51
1461	What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis. 2019 , 9, e024051	10
1460	Patterns of Membrane Protein Clustering in Peripheral Lymphocytes as Predictors of Therapeutic Outcomes in Major Depressive Disorder. 2019 , 10, 190	5
1459	Mood matters: a national survey on attitudes to depression. 2019 , 188, 1317-1327	3
1458	Re-evaluation of Significance and the Implications of Placebo Effect in Antidepressant Therapy. 2019 , 10, 143	3
1457	Predicting clinical course in major depressive disorder: The association between DM-TRD score and symptom severity over time in 1115 outpatients. 2019 , 36, 345-352	10
1456	Depression in the Primary Care Setting. 2019 , 380, 559-568	82
1455	Prognostic effect of serum BDNF levels in late-life depression: Moderated by childhood trauma and SSRI usage?. 2019 , 103, 276-283	4
1454	Coping with the forced swim stressor: Current state-of-the-art. 2019 , 364, 1-10	112

1453	Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators. 2019 , 249, 242-252	26
1452	Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. 2019 , 33, 494-501	24
1451	Personalized Psychiatry. 2019 ,	12
1450	Protecting the environment from psychoactive drugs: Problems for regulators illustrated by the possible effects of tramadol on fish behaviour. 2019 , 664, 915-926	23
1449	Development and validation of a prediction model for the probability of responding to placebo in antidepressant trials: a pooled analysis of individual patient data. 2019 , 22, 10-16	7
1448	Subtypes of treatment-resistant depression determined by a latent class analysis in a Chinese clinical population. 2019 , 249, 82-89	5
1447	Big Data Guided Interventions: Predicting Treatment Response. 2019 , 53-76	3
1446	Agomelatine for depression: expanding the horizons?. 2019 , 20, 647-656	24
1445	Editorial for Treatment-Resistant Depression (TRD). 2019 , 22, 83-84	4
1444	Review: In older adults with acute major depression, SNRIs, but not SSRIs, increase adverse events vs placebo. 2019 , 171, JC39	
1443	Review: In generalized anxiety disorder, network meta-analysis shows efficacy and tolerability of various drugs. 2019 , 170, JC54	
1442	Lost Evidence From Registered Large Long-Unpublished Randomized Controlled Trials: A Survey. 2019 , 171, 300-301	10
1441	Complementary therapies for clinical depression: an overview of systematic reviews. 2019 , 9, e028527	27
1440	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). 2019 , 80,	17
1439	P.193 Reboxetine, but not paroxetine enhances the endurance capacity in treadmill test in rats. 2019 , 29, S148-S149	
1438	Innovative Psychiatrieforschung im Blickpunkt. 2019 , 21, 54-57	
1437	The impact of depression and anxiety treatment on biological aging and metabolic stress: study protocol of the MOod treatment with antidepressants or running (MOTAR) study. 2019 , 19, 425	9
1436	Pharmacy-based management for depression in adults. 2019 , 12, CD013299	10

1435	Protocolo diagnóstico y terapéutico de la depresión. 2019 , 12, 5070-5074	1
1434	Psychological Treatment of Depression in Primary Care: Recent Developments. 2019 , 21, 129	56
1433	True and false positive rates for different criteria of evaluating statistical evidence from clinical trials. 2019 , 19, 218	6
1432	Depressive Disorders: Mechanisms, Measurement and Management. 2019 ,	2
1431	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. 2019 , 1, e237-e246	11
1430	Comparative efficacy of 13 antimicrobial dressings and different securement devices in reducing catheter-related bloodstream infections: A Bayesian network meta-analysis. 2019 , 98, e14940	6
1429	GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment responses in Chinese of Han ethnicity. 2019 , 98, e15456	3
1428	What are the chances for personalised treatment with antidepressants? Detection of patient-by-treatment interaction with a variance ratio meta-analysis. 2019 , 9, e034816	21
1427	The Herb-Drug Pharmacokinetic Interaction of Fluoxetine and Its Metabolite Norfluoxetine with a Traditional Chinese Medicine in Rats by LC-MS/MS. 2019 , 2019, 2471870	1
1426	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. 2019 , 19, 420	10
1425	Therapie der Depression â vom Gestern zum Morgen. 2019 , 20, 66-74	0
1424	Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials. 2019 , 98, e15786	3
1423	The Role of Exercise in Preventing and Treating Depression. 2019 , 18, 299-304	53
1422	Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis. 2019 , 160, 2186-2198	8
1421	Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up. 2019 , 15, 3247-3254	4
1420	Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better?. 2019 , 32, 348-354	34
1419	The Association Between Selective Serotonin Reuptake Inhibitors and Glycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2019 , 81, 570-583	11
1418	[Depression - the big black dog]. 2019 , 161, 45-48	

1417	The wh-questions of network meta-analyses. 2019 , 25, 396-398	1
1416	Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis. 2019 , 34, 65-75	10
1415	Staying on, and coming off, antidepressants: The experiences of 752 UK adults. 2019 , 88, 82-85	19
1414	How to choose an antidepressant medication. 2019 , 139, 280-291	9
1413	The evidence-based group-level symptom-reduction model as the organizing principle for mental health care: time for change?. 2019 , 18, 88-96	71
1412	Heat-killed lactobacilli alter both microbiota composition and behaviour. 2019 , 362, 213-223	42
1411	Is it time to end our complicity with pharmacocentricity?. 2019 , 28, 3-6	3
1410	Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. 2019 , 76, 31-40	62
1409	Interactions between whole-body heating and citalopram on body temperature, antidepressant-like behaviour, and neurochemistry in adolescent male rats. 2019 , 359, 428-439	3
1408	Comparison of Cognitive Intervention Strategies for Older Adults With Mild to Moderate Alzheimer's Disease: A Bayesian Meta-analytic Review. 2019 , 20, 347-355	7
1407	Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. 2019 , 214, 42-51	44
1406	Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. 2019 , 14, 81-89	38
1405	No Magic Pill: A Prescription for Enhanced Shared Decision-Making for Depression Treatment. 2019 , 32, 6-9	3
1404	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. 2019 , 34, 180-198	357
1403	Nitric oxide signalling and antidepressant action revisited. 2019 , 377, 45-58	22
1402	Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2. 2019 , 22, 278-285	36
1401	Mirtazapine for chronic breathlessness? A review of mechanistic insights and therapeutic potential. 2019 , 13, 173-180	8
1400	Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder. 2019 , 19, 24	2

1399	Recent Developments in the Treatment of Depression. 2019 , 50, 257-269		16
1398	A discrete-choice experiment to assess treatment modality preferences of patients with depression. 2019 , 22, 178-186		9
1397	Vortioxetine for depression: the evidence for its current use in the UK: COMMENTARY ON COCHRANE CORNER. 2019 , 25, 3-6		
1396	Depression and prostate cancer: A focused review for the clinician. 2019 , 37, 282-288		32
1395	Pharmacotherapy Effectiveness in Treating Depression After Traumatic Brain Injury: A Meta-Analysis. 2019 , 31, 220-227		9
1394	Rates and Determinants of Use of Pharmacotherapy and Psychotherapy by Patients With Major Depressive Disorder. 2019 , 70, 262-270		7
1393	Physical Exercise in Major Depression: Reducing the Mortality Gap While Improving Clinical Outcomes. 2018 , 9, 762		34
1392	Allowing for uncertainty due to missing and LOCF imputed outcomes in meta-analysis. 2019 , 38, 720-737		9
1391	Rheumatoid arthritis and depression: an inflammatory perspective. 2019 , 6, 164-173		125
1390	Reducing the global burden of depression: a Lancet-World Psychiatric Association Commission. <i>Lancet, The</i> , 2019 , 393, e42-e43	40	78
1389	Different Types and Acceptability of Psychotherapies for Acute Anxiety Disorders in Children and Adolescents: A Network Meta-analysis. 2019 , 76, 41-50		34
1388	The right to choose treatment-without-treatment: respecting civil rights or an unprecedented manifestation of 'reverse stigma'?. 2019 , 31, 56-58		3
1387	Changes in cognitive distortions and affectivity levels in adolescent depression after acute phase fluoxetine treatment. 2019 , 24, 4-13		1
1386	Meta-Review: Network Meta-Analyses in Child and Adolescent Psychiatry. 2019 , 58, 167-179		8
1385	Efficacy of inpatient psychotherapy for major depressive disorder: a meta-analysis of controlled trials. 2019 , 139, 322-335		8
1384	Cochrane crisis: Secrecy, intolerance and evidence-based values. 2019 , 49, e13058		6
1383	Predicting treatment response to antidepressant medication using early changes in emotional processing. 2019 , 29, 66-75		24
1382	Pharmaceutical cocrystals: from serendipity to design to application. 2019 , 24, 796-804		123

1381	Effects of cognitive judgement bias and acute antidepressant treatment on sensitivity to feedback and cognitive flexibility in the rat version of the probabilistic reversal-learning test. 2019 , 359, 619-629	9
1380	Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. 2019 , 194, 185-198	18
1379	Discontinuation of antidepressants in suicides findings from the Friuli Venezia Giulia Region, Italy, 2005-2014. 2019 , 124, 312-320	1
1378	Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents. 2019 , 24, 1478-1488	57
1377	Placebo response rates and potential modifiers in double-blind randomized controlled trials of second and newer generation antidepressants for major depressive disorder in children and adolescents: a systematic review and meta-regression analysis. 2020 , 29, 253-273	11
1376	Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. 2020 , 41, 1687-1696	90
1375	Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine. 2020 , 25, 372-379	1
1374	Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission. 2020 , 25, 46-48	9
1373	Dealing with missing outcome data in meta-analysis. 2020 , 11, 2-13	16
1372	Translating the BDI and BDI-II into the HAMD and vice versa with equipercetile linking. 2019 , 29, e24	20
1371	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. 2020 , 177, 143-154	29
1370	Brain oscillation-synchronized stimulation of the left dorsolateral prefrontal cortex in depression using real-time EEG-triggered TMS. 2020 , 13, 197-205	25
1369	Comparative efficacy of exercise and anti-hypertensive pharmacological interventions in reducing blood pressure in people with hypertension: A network meta-analysis. 2020 , 27, 247-255	20
1368	Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. 2020 , 11, 181-217	239
1367	Should antidepressants be used for major depressive disorder?. 2020 , 25, 130	35
1366	The micro-to-macro realities of antidepressant taking: Users' experiences in the context of contested science and industry promotion. 2020 , 19, 1219-1237	1
1365	Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials. 2020 , 53, 5-13	1
1364	Managing Depression with Herbal Formula: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2020 , 26, 8-24	9

1363	Shared parameter model for competing risks and different data summaries in meta-analysis: Implications for common and rare outcomes. 2020 , 11, 91-104	6
1362	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. 2020 , 260, 131-139	14
1361	Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. 2020 , 25, 1580-1591	24
1360	Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications. 2020 , 260, 483-488	
1359	Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. 2020 , 25, 1526-1536	17
1358	Connectivity of the Cognitive Control Network During Response Inhibition as a Predictive and Response Biomarker in Major Depression: Evidence From a Randomized Clinical Trial. 2020 , 87, 462-472	23
1357	Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder. 2020 , 262, 118-125	4
1356	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. 2020 , 131, 91-101	16
1355	Static and dynamic functional connectivity of the prefrontal cortex during resting-state predicts self-serving bias in depression. 2020 , 379, 112335	3
1354	Men's views of antidepressant treatment for depression, and their implications for community pharmacy practice. 2020 , 16, 1041-1049	2
1353	Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. 2020 , 45, 570-576	18
1352	Exercise Training for Improving Patient-Reported Outcomes in Patients With Advanced-Stage Cancer: A Systematic Review and Meta-Analysis. 2020 , 59, 734-749.e10	19
1351	A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. 2020 , 19, 92-107	89
1350	Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. 2020 , 265, 63-70	42
1349	Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). 2020 , 131, 474-528	411
1348	The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. 2020 , 284, 112749	42
1347	Novel Targets to Treat Depression: Opioid-Based Therapeutics. 2020 , 28, 40-59	13
1346	Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. 2020 , 34, 280-292	5

1345	Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder: Secondary Analysis of a Randomized Clinical Trial. 2020 , 77, 397-408	22
1344	Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity. 2020 , 11, 275-286	1
1343	Pharmacological management of post-stroke depression. 2020 , 20, 157-166	8
1342	No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. 2020 , 141, 401-409	6
1341	A survey of dog owners' perceptions on the use of psychoactive medications and alternatives for the treatment of canine behavior problems. 2020 , 35, 27-33	7
1340	Effect of dark chocolate on flow-mediated dilatation: Systematic review, meta-analysis, and dose-response analysis of randomized controlled trials. 2020 , 36, 17-27	3
1339	Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. 2020 , 74, 140-148	11
1338	Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder. 2019 , 22, 4	1
1337	The Positive and Negative Experiences of 342 Antidepressant Users. 2020 , 56, 744-752	3
1336	Randomized Controlled Trial of the Marriage Checkup: Depression Outcomes. 2020 , 46, 507-522	7
1335	Efficacy and Adverse Effects of Tranylcypromine and Tricyclic Antidepressants in the Treatment of Depression: A Systematic Review and Comprehensive Meta-analysis. 2020 , 40, 63-74	83
1334	Irish Medical Organisation Doolin Memorial Lecture 2019: rhetoric and reality in mental health-Ireland and the world. 2020 , 189, 1127-1134	
1333	Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis. 2020 , 99, 109836	46
1332	Gene expression signature of antidepressant treatment response/non-response in Flinders Sensitive Line rats subjected to maternal separation. 2020 , 31, 69-85	4
1331	Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. 2020 , 263, 258-266	6
1330	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. 2020 , 23, 88-95	5
1329	Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. 2020 , 25, 321-338	88
1328	Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression. 2020 , 23, 76-87	9

1327	The antidepressant standoff: why it continues and how to resolve it. 2020 , 50, 177-186	6
1326	Depression in the medically ill. 2020 , 54, 346-366	13
1325	Mental health is biological health: Why tackling "diseases of the mind" is an imperative for biological anthropology in the 21st century. 2020 , 171 Suppl 70, 87-117	17
1324	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. 2020 , 263, 353-366	4
1323	Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT. 2020 , 4, 427-438	1
1322	Microdosing psychedelics: Motivations, subjective effects and harm reduction. 2020 , 75, 102600	21
1321	Adherence to Antidepressants in Underserved Communities: A Comparison of Electronic Monitoring and Self-report Measures. 2020 , 56, 727-734	3
1320	Inhibitory Repetitive Transcranial Magnetic Stimulation to Treat Psychomotor Slowing: A Transdiagnostic, Mechanism-Based Randomized Double-Blind Controlled Trial. 2020 , 1,	11
1319	Influence of theta-burst transcranial magnetic stimulation over the dorsolateral prefrontal cortex on emotion processing in healthy volunteers. 2020 , 20, 1278-1293	5
1318	Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation. 2020 , 263, 118582	10
1317	Unipolar depression and dysthymia. 2020 , 48, 713-716	
1316	Selective activation of D1 dopamine receptors exerts antidepressant-like activity in rats. 2020 , 34, 1443-1448	0
1315	Efficacy, efficiency and safety of high-frequency repetitive transcranial magnetic stimulation applied more than once a day in depression: A systematic review. 2020 , 277, 986-996	6
1314	Self-Report for Measuring and Predicting Medication Adherence: Experts' Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics. 2020 , 14, 1823-1842	1
1313	Schema therapy versus cognitive behavioral therapy versus individual supportive therapy for depression in an inpatient and day clinic setting: study protocol of the OPTIMA-RCT. 2020 , 20, 506	4
1312	Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses. 2020 , 19, 1595-1604	4
1311	Efficacy outcomes in the MDD-1 India study: First episode major depressive disorder outcomes in antidepressant-treated real-world patients in India. 2020 , 34, 1098-1104	
1310	A metabolomic study on the anti-depressive effects of two active components from. 2020 , 48, 718-727	3

1309	Ideal and Reality: The Gap Between Evidence Derived From Randomized Controlled Trial-Based Meta-analysis and Real-World Clinical Practice in Antidepressant Strategy for Depression. 2020 , 40, 428-429	
1308	Antidepressants, the Hamilton Depression Rating Scale Conundrum, and Quality of Life. 2020 , 40, 339-341	
1307	Selective serotonin reuptake inhibitors in major depression disorder treatment: an umbrella review on systematic reviews. 2020 , 24, 357-370	1
1306	Allopregnanolone in postpartum depression: Role in pathophysiology and treatment. 2020 , 12, 100212	36
1305	Depressive symptoms are not associated with long-term integrated testosterone concentrations in hair. 2021 , 22, 288-300	0
1304	Psychiatry's Future: Biology, Psychology, Legislation, and "The Fierce Urgency of ". 2020 , 42, 189-192	2
1303	[The role of placebo and nocebo mechanisms in depressive diseases and their treatment]. 2020 , 91, 675-683	2
1302	Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. 2020 , 19, 651-660	48
1301	Optimal Dose of Selective Serotonin Reuptake Inhibitors, Venlafaxine, and Mirtazapine in Major Depression: A Systematic Review and Dose-Response Meta-Analysis. 2020 , 18, 211-219	3
1300	Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study. 2020 , 35, e2750	3
1299	Intravenous administration of sodium propionate induces antidepressant or prodepressant effect in a dose dependent manner. 2020 , 10, 19917	2
1298	Comparative efficacy and acceptability of traditional Chinese medicine for adult major depression: A protocol for network meta-analysis. 2020 , 99, e23199	
1297	Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials. 2020 , 11, 580858	7
1296	Glucocorticoids in the Physiological and Transcriptional Regulation of 5-HT1A Receptor and the Pathogenesis of Depression. 2020 , 1073858420975711	6
1295	Genetic counselling for the prevention of mental health consequences of cannabis use: A randomized controlled trial-within-cohort. 2021 , 15, 1306-1314	0
1294	National Survey of Decision-Making for Antidepressants and Educational Level. 2020 , 33, 80-90	2
1293	Elaphuri Davidiani Cornu Improves Depressive-Like Behavior in Mice and Increases Neurotrophic Factor Expression in Mouse Primary Astrocytes via cAMP and ERK-Dependent Pathways. 2020 , 11, 593993	2
1292	SSRI Treatment Response Prediction in Depression Based on Brain Activation by Emotional Stimuli. 2020 , 11, 538393	3

1291	Recovering from depression with repetitive transcranial magnetic stimulation (rTMS): a systematic review and meta-analysis of preclinical studies. 2020 , 10, 393	19
1290	Nefarious nausea: A systematic review and meta-analysis of the risks of nausea in the treatment of major depressive, obsessive-compulsive, and anxiety disorders with selective serotonin re-uptake inhibitors (SSRIs). 2020 , 1, 100016	
1289	Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment. 2020 , 15, 8893-8910	11
1288	Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent. 2021 , 55, 1033-1038	2
1287	Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial. 2020 , 21, 695	2
1286	The clinical effectiveness of an algorithm-guided treatment program for depression in specialized mental healthcare: A comparison with efficacy trials. 2020 , 275, 216-223	3
1285	O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment. 2020 , 11, 1002	8
1284	Raising Placebo Efficacy in Antidepressant Trials Across Decades Explained by Small-Study Effects: A Meta-Reanalysis. 2020 , 11, 633	2
1283	An old but still burning problem: Inter-rater reliability in clinical trials with antidepressant medication. 2020 , 276, 748-751	2
1282	Nutrition and depression: Summary of findings from the EU-funded MooDFOOD depression prevention randomised controlled trial and a critical review of the literature. 2020 , 45, 403-414	3
1281	Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France. 2020 , 40, 1009-1020	3
1280	Non-pharmacological interventions for postpartum depression: A protocol for systematic review and network meta-analysis. 2020 , 99, e21496	0
1279	Do environmentally relevant concentrations of fluoxetine and citalopram impair stress-related behavior in zebrafish (<i>Danio rerio</i>) embryos?. 2020 , 261, 127753	9
1278	The efficacy, ethics, & pitfalls of stimulants for justice system involved individuals. 2020 , 116, 120-129	
1277	SNRIs achieve faster antidepressant effects than SSRIs by elevating the concentrations of dopamine in the forebrain. 2020 , 177, 108237	7
1276	The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients. 2020 , 276, 991-1000	7
1275	Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis. 2020 , 129, 160-167	2
1274	Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine. 2020 , 34, 1105-1111	4

1273	Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. 2020 , 9,	7
1272	Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation. 2020 , 11, 782	29
1271	Antioxidant Potential of Psychotropic Drugs: From Clinical Evidence to In Vitro and In Vivo Assessment and toward a New Challenge for in Silico Molecular Design. 2020 , 9,	19
1270	Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder. 2021 , 21, 1031-1042	2
1269	Uso de antidepressivos e percepção de saúde entre adultos de 40 anos ou mais: estudo longitudinal.. 2020 , 49,	
1268	Predictors of receiving a diagnosis, referral and treatment of depression in people on antiretroviral therapy in South African primary care: a secondary analysis of data from a randomised trial. 2020 , 25, 1450-1466	1
1267	Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment. 2020 , 11, 717	10
1266	Studies on Tryptophan Metabolites in Patients of Major Monopolar Depression. 2020 ,	
1265	The trouble with antidepressants: why the evidence overplays benefits and underplays risks-an essay by John B Warren. 2020 , 370, m3200	11
1264	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. 2020 , 23, 571-577	2
1263	Treating Psychological Trauma in the Midst of COVID-19: The Role of Smartphone Apps. 2020 , 8, 402	6
1262	Preface. 2020 , xiii-xv	
1261	EditorsâNote. 2020 , xvii-xvii	
1260	Critical appraisal of clinical practice guidelines for depression in children and adolescents: A protocol for systematic review. 2020 , 99, e22384	0
1259	Laser Trabeculoplasty for Open-Angle Glaucoma: A Systematic Review and Network Meta-Analysis. 2021 , 229, 301-313	2
1258	Network meta-analysis of antiepileptic drugs in focal drug-resistant epilepsy. 2020 , 167, 106433	3
1257	Verordnung von Antidepressiva. 2020 , 49, 122-129	
1256	What Can Person-Centred Care in Dementia Learn from the Recovery Movement?. 2020 , 202-212	

1255 Epidemiology and Mental Health in Old Age. **2020**, 5-23

1254 Vascular Dementia. **2020**, 24-37

1253 Young-Onset Dementias. **2020**, 38-49

1252 Rare and Unusual Dementias. **2020**, 50-77

1251 Mania in Late Life. **2020**, 78-91

1250 Alcohol Misuse in Older People. **2020**, 92-104

1249 Drug Misuse in Older People. **2020**, 105-115

1248 Mental Health in Parkinson's Disease. **2020**, 116-128

1247 The Home Assessment in Old Age Psychiatry. **2020**, 129-138

1246 Driving in Dementia. **2020**, 139-148

1245 Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment. **2020**, 149-160

1244 Biomarkers and the Diagnosis of Preclinical Alzheimer's Disease. **2020**, 161-172

1243 To Scan or Not to Scan. **2020**, 173-190

1242 Supporting Self-Management in Early Dementia. **2020**, 191-201

1241 Psychosocial Interventions in Dementia. **2020**, 213-222

1240 Palliative Care in Dementia. **2020**, 223-242

1239 Review of Treatment for Late-Life Depression. **2020**, 243-253

1238 Reducing the Healthcare Burden of Delirium. **2020**, 254-265

1237	Controlling the Confusion. 2020 , 266-278	
1236	Residence Capacity. 2020 , 305-316	
1235	Concluding Reflections. 2020 , 328-329	
1234	Index. 2020 , 330-344	
1233	Adjunctive bright light treatment with gradual advance in unipolar major depressive disorder with evening chronotype - A randomized controlled trial. 2020 , 1-10	7
1232	Introductory Comments. 2020 , 1-4	
1231	Mental Health Laws from All UK Jurisdictions. 2020 , 279-292	
1230	Deprivation of Liberty. 2020 , 293-304	
1229	Understanding the Person with Dementia. 2020 , 317-327	
1228	The management of depression following traumatic brain injury: A systematic review with meta-analysis. 2020 , 34, 1287-1304	8
1227	Depressive symptoms are associated with worse cognitive prognosis in patients with newly diagnosed idiopathic Parkinson disease. 2020 , 20, 880-890	4
1226	Can we prevent seasonal affective disorder (SAD) with melatonergic agents?. 2020 , 26, 193-197	
1225	What Good Are Treatment Effects without Treatment? Mental Health and the Reluctance to Use Talk Therapy. 2020 ,	
1224	Association between genetic polymorphism and antidepressants in major depression: a network meta-analysis. 2020 , 21, 963-974	1
1223	Individual response to antidepressants for depression in adults-a meta-analysis and simulation study. 2020 , 15, e0237950	10
1222	A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report. 2020 , 10, 2045125320950124	8
1221	The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice. 2020 , 237, 3715-3728	5
1220	An Epigenetic Perspective on Lifestyle Medicine for Depression: Implications for Primary Care Practice.. 2022 , 16, 76-88	1

1219	Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials. 2020 , 20, 437	2
1218	Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis. 2020 , 1-9	2
1217	Comorbid depression in medical diseases. 2020 , 6, 69	62
1216	Is Agomelatine Associated with Less Sedative-Hypnotic Usage in Patients with Major Depressive Disorder? A Nationwide, Population-Based Study. 2020 , 16, 1727-1736	1
1215	The 'patient voice': patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. 2020 , 10, 2045125320967183	19
1214	Epidemiology of depressive disorders in people living with hypertension in Africa: a systematic review and meta-analysis. 2020 , 10, e037975	2
1213	Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia. 2020 , 16, 2929-2941	2
1212	Directed Evolution of a Selective and Sensitive Serotonin Sensor via Machine Learning. 2020 , 183, 1986-2002.e34	24
1211	UPLC-MS/MS for simultaneous quantification of vortioxetine and its metabolite Lu AA34443 in rat plasma and its application to drug interactions. 2020 , 13, 8218-8225	1
1210	[Suicidality in schizophrenic psychosis: a current overview]. 2021 , 92, 1186-1195	
1209	Defining Wellness. 2020 , 1-12	
1208	Wellness Interventions in the Workplace. 2020 , 248-257	
1207	Engaging the Five Senses. 2020 , 448-462	
1206	Family Relations, Friendships, and Love. 2020 , 553-564	
1205	Index. 2020 , 623-636	
1204	Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis. 2020 , 10, 18880	5
1203	Low-hanging fruit for getting back on your feet: A critical review of diet and exercise interventions for depression. 2020 , 1, 100019	1
1202	Screening and Assessment Methods for Wellness. 2020 , 13-22	

1201 The Biopsychosocial Assessment. **2020**, 23-36

1200 Wellness Measurement. **2020**, 37-44

1199 The Wellness Treatment Plan. **2020**, 45-56

1198 The Concept of Wellness in Psychiatric and Substance-Use Disorders. **2020**, 57-65

1197 Neurological and Neurosurgical Disorders and Wellness. **2020**, 66-78

1196 Cardiovascular and Pulmonary Wellness. **2020**, 79-86

1195 Gastrointestinal System and Wellness. **2020**, 87-97

1194 Wellness and the Genito-Urinary System. **2020**, 98-115

1193 Reproductive System. **2020**, 116-134

1192 Allergic, Infectious, and Immunological Processes. **2020**, 135-159

1191 Wellness in Endocrine and Metabolic Disorders. **2020**, 160-176

1190 Wellness in Older Individuals. **2020**, 188-198

1189 Wellness in Children and Adolescents. **2020**, 199-208

1188 Wellness in Cancer and Neoplastic Diseases. **2020**, 225-236

1187 Wellness in Terminal Illness. **2020**, 237-247

1186 Wellness Interventions for Physicians and Healthcare Professionals. **2020**, 258-270

1185 Nutrition. **2020**, 271-291

1184 Exercise, Dance, Tai Chi, Pilates, and Alexander Technique. **2020**, 315-323

1183 Sleep, Rest, and Relaxation in Improving Wellness. **2020**, 324-331

1182 Sex, Intimacy, and Well-Being. **2020**, 332-344

1181 Mindfulness, Meditation, and Yoga. **2020**, 345-356

1180 Positive Neuropsychology, Cognitive Rehabilitation, and Neuroenhancement. **2020**, 365-377

1179 Acupuncture, Herbs, and Ayurvedic Medicine. **2020**, 378-393

1178 Massage, Humor, and Music. **2020**, 403-412

1177 Nature and Pets. **2020**, 413-422

1

1176 Resilience and Wellness. **2020**, 484-493

1175 Developing Purpose, Meaning, and Achievements. **2020**, 494-503

1174 Healing and Wellness. **2020**, 504-514

1173 Connection, Compassion, and Community. **2020**, 515-524

1172 Work, Love, Play, and Joie de Vivre. **2020**, 535-544

1171 Well-Being and Work-Life Balance. **2020**, 545-552

1170 The Role of Leisure, Recreation, and Play in Health and Well-Being. **2020**, 565-572

1169 Wellness Apps and Devices. **2020**, 605-622

0

1168 Wellness Interventions in Patients Living with Chronic Medical Conditions. **2020**, 177-187

1167 Pharmaceuticals and Alternatives for Wellness. **2020**, 302-314

1166 Emotional Intelligence and Its Role in Sustaining Fulfillment in Life. **2020**, 463-473

1165 Wellness and Whole-Person Care. **2020**, 573-581

1164 Analgesic medicines for adults with low back pain: protocol for a systematic review and network meta-analysis. **2020**, 9, 255

2

1163 Wellness in Pain Disorders. **2020**, 209-224

1162 Forgiveness, Gratitude, and Spirituality. **2020**, 357-364

1161 The Role of Aesthetics in Wellness. **2020**, 394-402

0

1160 Circadian Rhythm in the Digital Age. **2020**, 423-434

1159 The Arts in Health Settings. **2020**, 435-447

1158 Wellness Interventions for Chronicity and Disability. **2020**, 525-534

1157 The Personalized Wellness Life Plan. **2020**, 582-597

1156 Wellness Measures. **2020**, 597-604

1155 Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. **2020**, 50, 2655-2666

7

1154 Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. **2020**, 86, 2114-2122

14

1153 Comparative prevention potential of 10 mouthwashes on intolerable oral mucositis in cancer patients: A Bayesian network analysis. **2020**, 107, 104751

3

1152 Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol. **2020**, 23, 52-56

13

1151 Oxidative Stress at the Crossroads of Aging, Stroke and Depression. **2020**, 11, 1537-1566

27

1150 The comparative effectiveness of physical exercise interventions in individuals with chronic non-specific neck pain: protocol for a network meta-analysis. **2020**, 10, e034846

1

1149 Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine. **2020**, 18, 181-192

2

1148 Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus. **2020**, 10, 130

6

1147	A phenome-wide association and Mendelian Randomisation study of polygenic risk for depression in UK Biobank. 2020 , 11, 2301	31
1146	Is Postpartum Depression Different From Depression Occurring Outside of the Perinatal Period? A Review of the Evidence. 2020 , 18, 106-119	15
1145	Pharmacological and behavioral treatment for trichotillomania: An updated systematic review with meta-analysis. 2020 , 37, 715-727	20
1144	Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats. 2020 , 237, 2201-2212	6
1143	A mechanistic account of serotonin's impact on mood. 2020 , 11, 2335	11
1142	Drugs to Treat Depression. 2020 , 227-267	
1141	Environmental Enrichment and Physical Exercise Attenuate the Depressive-Like Effects Induced by Social Isolation Stress in Rats. 2020 , 11, 804	11
1140	Similarities and dissimilarities in the effects of benzodiazepines and specific serotonin reuptake inhibitors (SSRIs) in the defensive marble burying test: A systematic review and meta-analysis. 2020 , 36, 38-49	3
1139	Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. 2020 , 13, 655-670	11
1138	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. 2020 , 28, 933-945	6
1137	Antidepressant treatment for postnatal depression. 2020 ,	1
1136	Suicide risk, psychological distress and treatment preferences in men presenting with prototypical, externalising and mixed depressive symptomology. 2020 , 1-8	5
1135	Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?. 2020 , 390, 112628	9
1134	Drug repositioning for psychiatric and neurological disorders through a network medicine approach. 2020 , 10, 141	11
1133	Glucocorticoids negatively regulates chaperone mediated autophagy and microautophagy. 2020 , 528, 199-205	3
1132	Authors' reply. 2020 , 216, 345-346	
1131	Assessing adjunctive treatments for bipolar depression. 2020 , 7, 478-479	1
1130	Assessment of a Prediction Model for Antidepressant Treatment Stability Using Supervised Topic Models. 2020 , 3, e205308	6

1129	The association of COMT genotype with bupropion treatment response in the treatment of major depressive disorder. 2020 , 10, e01692	1
1128	Expectation-induced placebo effect on acute sadness in women with major depression: An experimental investigation. 2020 , 274, 920-928	8
1127	Needlessly controversial: the reporting of pharmaco- and psycho-therapy for the treatment of depression in the UK media. 2020 , 1-6	0
1126	Research Review: Brain network connectivity and the heterogeneity of depression in adolescence - a precision mental health perspective. 2020 , 61, 1282-1298	12
1125	Comparative Efficacy of Chinese Herbal Injections for Pulmonary Heart Disease: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. 2020 , 11, 634	5
1124	When and how to use lithium. 2020 , 142, 161-172	10
1123	Dogs bark, but the caravan goes on: A discussion on the meta-analysis of antidepressants by Andrea Cipriani et al. 2020 , 31, 149-155	1
1122	Spirituality, religion, and mood disorders. 2020 , 1-25	0
1121	Real-world effect of antidepressants for depressive disorder in primary care: protocol of a population-based cohort study. 2020 , 23, 122-126	3
1120	Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. 2020 , 7, 581-601	58
1119	Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders. 2020 , 274, 315-325	15
1118	Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level. 2020 , 124, 106-117	2
1117	Triple reuptake inhibition of serotonin, norepinephrine, and dopamine increases the tonic activation of β adrenoceptors in the rat hippocampus and dopamine levels in the nucleus accumbens. 2020 , 103, 109987	2
1116	Comparison between acupuncture and cognitive behavioral therapy for primary insomnia: A protocol for systematic review and network meta-analysis. 2020 , 99, e20453	2
1115	Inflammation as a treatment target in mood disorders: review. 2020 , 6, e60	20
1114	Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOT) metric for a personalised psychiatry. 2020 , 18, 170	10
1113	Fluoxetine in the Management of Major Depressive Disorder in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials. 2021 , 56, 525-531	1
1112	The Role and the Effect of Magnesium in Mental Disorders: A Systematic Review. 2020 , 12,	28

1111	Placebo response rates in trials of antidepressant drugs in adults with clinical depression: Increasing, decreasing, constant or all of the above?. 2020 , 271, 139-144		1
1110	Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves. 2020 , 1-9		2
1109	Drug-Induced Liver Injury (DILI) in Patients with Depression Treated with Antidepressants: A Retrospective Multicenter Study. 2020 , 53, 60-64		0
1108	Metformin Enhances Antidepressant/Antipsychotic Combination Therapy of Schizophrenia With Comorbid Depression in a Murine Model. 2020 , 14, 517		5
1107	Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study. 2020 , 11, 453		3
1106	Influence of Zuojin Pill on the Metabolism of Venlafaxine in Vitro and in Rats and Associated Herb-Drug Interaction. 2020 , 48, 1044-1052		2
1105	The influence of antidepressant and psychotherapy treatment adherence on future work leaves for patients with major depressive disorder. 2020 , 20, 320		1
1104	Vortioxetine vs placebo in major depressive disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan. 2020 , 74, 330-332		
1103	What do we know about long-term treatment outcomes for severe depressive disorders?. 2020 , 6, e28		1
1102	Health-related Internet use and treatment adherence: A transdiagnostic comparison of outpatients with major depressive disorder and schizophrenia. 2020 , 9, 174-184		2
1101	Amitriptyline and Depressions. 2020 , 1-19		
1100	Generating comparative evidence on new drugs and devices after approval. <i>Lancet, The</i> , 2020 , 395, 998-1010	1010	23
1099	Generating comparative evidence on new drugs and devices before approval. <i>Lancet, The</i> , 2020 , 395, 986-997	40	28
1098	Approach to Evaluating and Managing Adult Attention-Deficit/Hyperactivity Disorder in Primary Care. 2020 , 28, 100-106		4
1097	Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. 2020 , 34, 506-513		10
1096	Association between C-reactive protein and mood disorder in a representative sample of the Canadian population: analysis of CHMS data 2013-2014. 2020 , 111, 743-751		1
1095	Suicide Screening in Sturge-Weber Syndrome: An Important Issue in Need of Further Study. 2020 , 110, 80-86		3
1094	Pathways Connecting Late-Life Depression and Dementia. 2020 , 11, 279		38

1093	National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis. 2020 , 11, 35	40
1092	How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. 2020 , 20, 102	12
1091	Employment effects of healthcare policy: Evidence from the 2007 FDA black box warning on antidepressants. 2020 , 73, 102348	2
1090	Brand-Name Antidepressants Outperform Their Generic Counterparts in Preventing Hospitalization for Depression: The Real-World Evidence from Taiwan. 2020 , 23, 653-661	2
1089	Psychological aspects of infertility. A systematic review. 2020 , 48, 300060520932403	10
1088	Antidepressants and Risk of Type 2 Diabetes Mellitus: A Population-Based Nested Case-Control Study. 2020 , 40, 359-365	5
1087	Cognitive-Behavioural Correlates of Dysbiosis: A Review. 2020 , 21,	6
1086	Antidepressants do work after all. 2020 , 34, 1071-1073	2
1085	A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. 2020 , 275, 38-43	13
1084	The preclinical discovery and development of agomelatine for the treatment of depression. 2020 , 15, 1121-1132	4
1083	Vortioxetine improves rapid eye movement sleep behavior disorder: A case report. 2020 , 99, e21003	2
1082	Study of mental health outcomes associated with different brands of venlafaxine at the Kumeu medical centre from January 2017 to October 2018. 2020 , 10, 2045125320927309	
1081	Prescribing for moderate or severe unipolar depression in patients under the long-term care of UK adult mental health services. 2020 , 10, 2045125320930492	1
1080	Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants. 2020 , 89, 237-259	3
1079	Charting the landscape of graphical displays for meta-analysis and systematic reviews: a comprehensive review, taxonomy, and feature analysis. 2020 , 20, 26	9
1078	Editorial for "Ensemble Learning for Early-Response Prediction of Antidepressant Treatment in Major Depressive Disorder". 2020 , 52, 172-173	
1077	Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis: A Systematic Review and Network Meta-analysis. 2020 , 174, 341-349	24
1076	Do antidepressants promote neurogenesis in adult hippocampus? A systematic review and meta-analysis on naive rodents. 2020 , 210, 107515	21

1075	Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. 2020 , 15, e0229381	12
1074	Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data. 2020 , 30, 3771-3780	6
1073	Comparative risk of Selective Serotonin Reuptake Inhibitors (SSRIs)-induced nausea among Chinese senile depression patients: A network meta-analysis of randomized-controlled trials. 2020 , 99, e19133	0
1072	Threat-sensitivity in affective disorders: A case-control study. 2020 , 266, 595-602	1
1071	Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. 2020 , 77, 607-617	20
1070	Predicting treatment dropout after antidepressant initiation. 2020 , 10, 60	12
1069	Antidepressant Discontinuation Syndrome: A Common but Underappreciated Clinical Problem. 2020 ,	
1068	Antidepressants in inflammatory bowel disease. 2020 , 17, 184-192	23
1067	Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults. 2020 ,	1
1066	Misinformed, misconducted, misguided and misrepresented meta-analyses. The use of antidepressants (AD) in major depressive disorders (MDD). 2020 , 22, 862-863	
1065	Escitalopram for recurrent isolated sleep paralysis. 2020 , 29, e13027	1
1064	Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. 2020 , 237, 1521-1532	14
1063	Using filled prescription sequences to rank antidepressants according to their acceptability in the general population: The Constances cohort. 2020 , 123, 72-80	2
1062	An electroencephalographic signature predicts antidepressant response in major depression. 2020 , 38, 439-447	68
1061	Qualitative treatment-subgroup interactions in the antidepressant treatment of major depression: Application of QUINT to individual participant data from seven placebo-controlled randomized controlled trials. 2020 , 21-22, 100054	
1060	Protocol on transcranial alternating current stimulation for the treatment of major depressive disorder: a randomized controlled trial. 2020 , 133, 61-67	10
1059	Minocycline for Depressive Symptoms: a Meta-Analysis of Randomized, Double-Blinded, Placebo-Controlled Trials. 2020 , 91, 451-461	7
1058	The microbiota and the hypothalamus-pituitary-adrenocortical (HPA) axis, implications for anxiety and stress disorders. 2020 , 62, 76-82	44

1057	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. 2020 , 25, 102178	4
1056	Thyroid hormone treatment in the management of treatment-resistant unipolar depression: a systematic review and meta-analysis. 2020 , 141, 316-326	9
1055	Why people choose to participate in psychotherapy for depression: A qualitative study. 2020 , 27, 417-424	3
1054	Feeling down? A systematic review of the gut microbiota in anxiety/depression and irritable bowel syndrome. 2020 , 266, 429-446	49
1053	Deep Brain Stimulation of the Medial Forebrain Bundle in a Rodent Model of Depression: Exploring Dopaminergic Mechanisms with Raclopride and Micro-PET. 2020 , 98, 8-20	6
1052	Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. 2020 , 36, 875-882	3
1051	A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder. 2020 , 265, 233-238	8
1050	Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis. 2020 , 18, 100219	7
1049	Fast-acting antidepressant-like effects of Reelin evaluated in the repeated-corticosterone chronic stress paradigm. 2020 , 45, 1707-1716	12
1048	Revisiting the validity of the mouse tail suspension test: Systematic review and meta-analysis of the effects of prototypic antidepressants. 2020 , 112, 39-47	8
1047	Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after stroke. 2020 , 1, CD003437	16
1046	Pharmacological management of depression: Japanese expert consensus. 2020 , 266, 626-632	11
1045	S-ketamine induces acute changes in the proteome of the mouse amygdala. 2020 , 216, 103679	2
1044	Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. 2020 , 127, 303-308	2
1043	Malaysian macroalga Hauck attenuates high dose corticosterone-mediated oxidative damage in PC12 cells mimicking the effects of depression. 2020 , 27, 1435-1445	4
1042	Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population. 2020 , 76, 807-814	3
1041	Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review. 2020 , 267, 185-190	7
1040	Non-pharmacological and pharmacological approaches for psychiatric disorders: Re-appraisal and insights from zebrafish models. 2020 , 193, 172928	10

1039	The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort. 2020 , 40, 137-144	7
1038	CINeMA: An approach for assessing confidence in the results of a network meta-analysis. 2020 , 17, e1003082	214
1037	Microbiota-Orientated Treatments for Major Depression and Schizophrenia. 2020 , 12,	19
1036	Feasibility and Efficacy of the Addition of Heart Rate Variability Biofeedback to a Remote Digital Health Intervention for Depression. 2020 , 45, 75-86	10
1035	Neuroimaging as a Tool for Individualized Treatment Choice in Depression: the Past, the Present and the Future. 2020 , 7, 32-39	3
1034	Associations between food insecurity and psychotropic medication use among women living with HIV in the United States. 2020 , 29, e113	4
1033	A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. 2020 , 35, 137-146	12
1032	Natural language processing for structuring clinical text data on depression using UK-CRIS. 2020 , 23, 21-26	17
1031	Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials. 2020 , 10, 117	10
1030	CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. 2020 , 16, e1080	43
1029	The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports. 2020 , 29, e120	5
1028	Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. 2020 , 269, 154-184	42
1027	Neuronavigation-Guided rTMS for the Treatment of Depressive Patients With Suicidal Ideation: A Double-Blind, Randomized, Sham-Controlled Trial. 2020 , 108, 826-832	7
1026	CSTI-300 (SMP-100); a Novel 5-HT Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome. 2020 , 373, 122-134	4
1025	Minocycline as adjunctive treatment for treatment-resistant depression: study protocol for a double blind, placebo-controlled, randomized trial (MINDEP2). 2020 , 20, 173	11
1024	Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. 2020 , 15, e0231700	14
1023	Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. 2020 , 9, 77	3
1022	Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. 2020 , 11, 94	40

1021	Translating the promise of 5HT receptor agonists for the treatment of depression. 2021 , 51, 1111-1120	6
1020	Efficacy and effectiveness studies of depression are not well-differentiated in the literature: a systematic review. 2021 , 26, 28-30	1
1019	Visualizing the evolution of evidence: Cumulative network meta-analyses of new generation antidepressants in the last 40 years. 2021 , 12, 74-85	2
1018	Factors that impact fragility index and their visualizations. 2021 , 27, 356-364	6
1017	Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. 2021 , 105, 110016	8
1016	The Kilim plot: A tool for visualizing network meta-analysis results for multiple outcomes. 2021 , 12, 86-95	6
1015	Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. 2021 , 238, 1265-1278	21
1014	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LITMUS trials. 2021 , 38, 114-123	3
1013	Predictors of poor 6-week outcome in a cohort of major depressive disorder patients treated with antidepressant medication: the role of entrapment. 2021 , 75, 38-48	1
1012	Effectiveness comparisons of various psychosocial therapies for children and adolescents with depression: a Bayesian network meta-analysis. 2021 , 30, 685-697	4
1011	Sleep deprivation as treatment for depression: Systematic review and meta-analysis. 2021 , 143, 22-35	12
1010	Agomelatine confers neuroprotection against cisplatin-induced hippocampal neurotoxicity. 2021 , 36, 339-349	3
1009	The effect of geniposide on chronic unpredictable mild stress-induced depressive mice through BTK/TLR4/NF- κ B and BDNF/TrkB signaling pathways. 2021 , 35, 932-945	9
1008	Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression. 2021 , 104, 110036	2
1007	Metamizole but not ibuprofen reduces the plasma concentration of sertraline: Implications for the concurrent treatment of pain and depression/anxiety disorders. 2021 , 87, 1111-1119	2
1006	Stages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study. 2021 , 278, 443-452	2
1005	Culturally adapted psychotherapies for depressed adults: A systematic review and meta-analysis. 2021 , 278, 296-310	5
1004	Network meta-analysis results against a fictional treatment of average performance: Treatment effects and ranking metric. 2021 , 12, 161-175	0

1003	Depression: Biological markers and treatment. 2021 , 105, 110139	17
1002	The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study. 2021 , 36, 1-11	3
1001	Effects of non-pharmacological interventions as vaccine adjuvants in humans: a systematic review and network meta-analysis. 2021 , 15, 245-271	1
1000	Modulation of premotor cortex response to sequence motor learning during escitalopram intake. 2021 , 41, 1449-1462	2
999	Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. 2021 , 24, 314-321	1
998	Towards precision medicine: What are the stratification hypotheses to identify homogeneous inflammatory subgroups. 2021 , 45, 108-121	1
997	Brexanolone in Postpartum Depression: Analyses to Help Inform Clinical Decision-Making. 2021 , 30, 385-392	3
996	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. 2021 , 78, 270-280	33
995	Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis. 2021 , 66, 274-288	7
994	Remission of depression is associated with asymmetric hemispheric variation in EEG complexity before antidepressant treatment. 2021 , 281, 872-879	0
993	Psychological interventions to prevent the onset of depressive disorders: A meta-analysis of randomized controlled trials. 2021 , 83, 101955	16
992	Oleate-induced aggregation of LC3 at the trans-Golgi network is linked to a protein trafficking blockade. 2021 , 28, 1733-1752	4
991	Cause-specific life years lost in individuals with treatment-resistant depression: A Danish nationwide register-based cohort study. 2021 , 280, 250-257	4
990	Is short-term antidepressant treatment effective and safe in bipolar depression? Results from an observational multicenter study. 2021 , 36, e2773	2
989	The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. 2021 , 280, 140-147	1
988	Cost-Effectiveness of Providing the Depression Care for People With Cancer Program to Patients With Prostate Cancer in the United States. 2021 , 24, 216-226	0
987	A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. 2021 , 37, 311-319	1
986	Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis. 2021 , 21, 200-215	0

985	The gut microbiota in anxiety and depression - A systematic review. 2021 , 83, 101943	81
984	Chronic Escitalopram Treatment Does Not Alter the Effects of Neonatal Stress on Hippocampal BDNF Levels, 5-HT Expression and Emotional Behaviour of Male and Female Adolescent Rats. 2021 , 58, 926-943	2
983	Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia. 2021 , 132, 144-150	1
982	Impact of psychiatrist support in home-based hospice care: A qualitative case-series review. 2021 , 29, 191-198	1
981	Depression in Primary Care. 2021 , 17, 37-43	0
980	Combining machine learning algorithms for prediction of antidepressant treatment response. 2021 , 143, 36-49	9
979	Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. 2021 , 27, 1022-1041	4
978	The role of comorbid anxiety in exercise and depression trials: Secondary analysis of the SMILE-II randomized clinical trial. 2021 , 38, 124-133	2
977	Abrupt cessation of reboxetine along alcohol deprivation results in alcohol intake escalation after reinstatement of drinking. 2021 , 26, e12957	2
976	Prefrontal resting-state connectivity and antidepressant response: no associations in the ELECT-TDCS trial. 2021 , 271, 123-134	1
975	Mood and Treatment Persistence in Inflammatory Bowel Disease: Time to Consider Integrated Models of Care?. 2021 , 19, 1111-1113	0
974	Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth. 2021 , 4, 452-460	19
973	Optogenetic and chemogenetic insights into the neurocircuitry of depression-like behaviour: A systematic review. 2021 , 53, 9-38	27
972	Effects of Psychopharmacological Medicines upon Driving Ability. 2021 , 1-15	
971	Novel therapeutic drug targets for bipolar disorder. 2021 , 393-404	
970	Preface. 2021 , xi-xii	
969	Brain Imaging and the Mechanisms of Antidepressant Action. 2021 , 248-260	
968	Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders. 2021 , 39-48	

967	Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder. 2021 , 236-247	
966	Combination Therapies and Switching of Agents in Depression and Bipolar Disorders. 2021 , 1-17	
965	Severity of congenital long QT syndrome disease manifestation and risk of depression, anxiety, and mortality: a nationwide study. 2021 ,	2
964	The effects of ACEI/ARB, aldosterone receptor antagonists and statins on preventing recurrence of atrial fibrillation: A protocol for systematic review and network meta-analysis. 2021 , 100, e24280	3
963	Praktische Psychopharmakologie. 2021 , 777-799	
962	Psychopharmacotherapy of Depressive Disorders. 2021 , 1-41	
961	Efficacy and safety of different agents, dosages and strategies of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials. 2021 , 99, e1041-e1050	2
960	Metallaphotoredox catalysis for multicomponent coupling reactions. 2021 , 23, 5379-5393	21
959	Causal effect of tooth loss on depression: evidence from a population-wide natural experiment in the USA. 2021 , 30, e38	8
958	Treatment resistant depression. 2021 , 33-84	
957	Magnetoencephalography Studies in Mood Disorders. 2021 , 192-205	
956	Plate Section (PDF Only). 2021 , 283-286	
955	Functional Near-Infrared Spectroscopy Studies in Mood Disorders. 2021 , 166-174	
954	Mood Disorders. 2021 ,	
953	Neuroimaging Studies of Effects of Psychotherapy in Depression. 2021 , 261-272	
952	Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder. 2022 , 271, 493-524	3
951	Long-term antidepressant use in general practice: a qualitative study of GPs' views on discontinuation. 2021 , 71, e508-e516	4
950	Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: review of recent studies and recommendations. 2021 , 15, 137-159	11

949	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease. 2021 , 3, vdab028	4
948	Antidepressant effects of total iridoids of via the intestinal flora-blood-brain barrier pathway. 2021 , 59, 912-921	4
947	Neuroimaging Brain Inflammation in Mood Disorders. 2021 , 121-134	
946	Response and Remission in Care-as-Usual, Waiting Lists and Pill Placebo Conditions in Psychotherapy Trials for Depression: A Meta-Analysis.	
945	An Overview of Machine Learning Applications in Mood Disorders. 2021 , 206-218	
944	Prior Choices of Between-Study Heterogeneity in Contemporary Bayesian Network Meta-analyses: an Empirical Study. 2021 , 36, 1049-1057	1
943	Chronobiology and Chronotherapy in Depression: Current Knowledge and Chronotherapeutic Promises. 2021 , 16, 179-193	0
942	Low SSRI dosing in clinical practice-a register-based longitudinal study. 2021 , 143, 434-443	1
941	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma. 2021 , 3, vdab029	1
940	Mood Disorders and Depression. 2021 , 283-302	
939	Physical activity and exercise for the prevention and management of anxiety. 369-384	2
938	Efficacy and safety of traditional Chinese patent medicine on carotid artery atherosclerosis in adults: A network meta-analysis protocol. 2021 , 100, e24406	1
937	Creative, Person-Centered Narrative Psychopharmacotherapy of Depression. 2021 , 1305, 463-492	1
936	The effect of sertraline on emotional processing: secondary analyses of the PANDA randomised controlled trial. 2021 , 1-8	1
935	Electrophysiological Biomarkers for Mood Disorders. 2021 , 175-191	1
934	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. 2021 , 19, 76-85	
933	Heterogeneous trajectory of depressive symptoms after repeated subcutaneous esketamine injections. 2021 , 3, 100053	1
932	Transcranial alternating current stimulation for treating depression: a randomized controlled trial.. 2022 , 145, 83-91	1

931 Depression. **2021**, 77-97

930 Systematic Reviews and Meta-analytic Methods in Clinical Psychology. **2021**,

0

929 Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update. **2021**, 11, 20451253211034320

2

928 Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. **2021**, 1-19

927 Agomelatine for postpartum depression and breastfeeding. **2021**, 11, 20451253211022172

1

926 Melatonin receptors, brain functions, and therapies. **2021**, 179, 345-356

3

925 Neuroanatomical Findings in Bipolar Disorder. **2021**, 16-27

924 Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders. **2021**, 105-120

923 Magnetic Resonance Spectroscopy Investigations of Bioenergy and Mitochondrial Function in Mood Disorders. **2021**, 83-104

922 Brain Imaging Methods in Mood Disorders. **2021**, 1-6

921 Effects of Lithium on Brain Structure in Bipolar Disorder. **2021**, 219-235

920 Depression during pregnancy amidst COVID-19. **2021**, 49, 155-156

0

919 Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. **2021**, 12, 640241

6

918 A male case of frontotemporal lobar degeneration with behavioural and psychiatric symptoms responding to a low dose of escitalopram. **2021**, 21, 255-257

917 Antidepressants fluoxetine and amitriptyline induce alterations in intestinal microbiota and gut microbiome function in rats exposed to chronic unpredictable mild stress. **2021**, 11, 131

13

916 Evaluation of a Blended Relapse Prevention Program for Anxiety and Depression in General Practice: Qualitative Study. **2021**, 5, e23200

1

915 Topological network mechanisms of clinical response to antidepressant treatment in drug-naive major depressive disorder. **2021**, 84, 82-90

1

914 Efficacy, acceptability, and safety of antidepressants for low back pain: a systematic review and meta-analysis. **2021**, 10, 62

6

913	Antidepressant treatment for postnatal depression. 2021 , 2, CD013560	2
912	Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. 2021 , 1-9	2
911	Brexipiprazole versus placebo or other antidepressive agents for treating depression.	1
910	Choosing an antidepressant. 2021 , 44, 12-15	3
909	Zinc as an adjunct to antidepressant medication: a meta-analysis with subgroup analysis for different levels of treatment response to antidepressants. 2021 , 1-11	1
908	Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. 2021 ,	5
907	Psychophysiological responses to group cognitive-behavioral therapy in depressive patients. 1	1
906	Why Is Exercise Underutilized in Clinical Practice Despite Evidence It Is Effective? Lessons in Pragmatism From the Inclusion of Exercise in Guidelines for the Treatment of Depression in the British National Health Service. 2021 , 10, 29-50	1
905	Can increased cognitive load help people with subthreshold depression to forget negative information?. 2021 , 283, 384-394	1
904	How can we estimate QALYs based on PHQ-9 scores? Equipercentile linking analysis of PHQ-9 and EQ-5D. 2021 ,	4
903	Fine-tuning pharmacological properties of mirtazapine antidepressant drug: a theoretical study. 2021 , 1-9	1
902	Is tDCS a potential first line treatment for major depression?. 2021 , 33, 250-265	1
901	Diastereoselective and Stereodivergent Synthesis of 2-Cinnamylpyrrolines Enabled by Photoredox-Catalyzed Iminoalkenylation of Alkenes. 2021 , 133, 9758-9765	4
900	EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial. 2021 , 44, 14-22	5
899	Xiaochaihu decoction for nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis. 2021 , 100, e25267	0
898	Neuroendocrine Assessment of Dopaminergic Function during Antidepressant Treatment in Major Depressed Patients. 2021 , 11,	0
897	The utility of the health belief model variables in predicting help-seeking intention for depressive symptoms. 2021 , 56, 233-244	
896	Desvenlafaxine in the treatment of major depression: an updated overview. 2021 , 22, 1087-1097	0

895	Intra-Articular Injections of Platelet-Rich Plasma, Adipose Mesenchymal Stem Cells, and Bone Marrow Mesenchymal Stem Cells Associated With Better Outcomes Than Hyaluronic Acid and Saline in Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. 2021 , 37, 2298-2314.e10	4
894	Borrowing Hydrogen for Organic Synthesis. 2021 , 7, 570-585	35
893	Diastereoselective and Stereodivergent Synthesis of 2-Cinnamylpyrrolines Enabled by Photoredox-Catalyzed Iminoalkenylation of Alkenes. 2021 , 60, 9672-9679	16
892	GW117: A novel serotonin (5-HT) receptor antagonist and melatonin (MT /MT) receptor agonist with potential antidepressant-like activity in rodents. 2021 , 27, 702-713	2
891	Comparing the Evidential Strength for Psychotropic Drugs: A Bayesian Meta-Analysis.	
890	Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. 2021 , 282, 1011-1020	0
889	Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. 2021 , 15, 711-722	1
888	Effects of n-3 Polyunsaturated Fatty Acid Supplementation in the Prevention and Treatment of Depressive Disorders-A Systematic Review and Meta-Analysis. 2021 , 13,	3
887	Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis. 2021 , 282, 1153-1160	9
886	Efficacy of onabotulinumtoxinA in the treatment of unipolar major depression: Systematic review, meta-analysis and meta-regression analyses of double-blind randomised controlled trials. 2021 , 35, 910-918	1
885	Second-generation antidepressants for treatment of seasonal affective disorder. 2021 , 3, CD008591	2
884	Comparative efficacy and acceptability of psychological interventions for the treatment of adult outpatients with anorexia nervosa: a systematic review and network meta-analysis. 2021 , 8, 215-224	19
883	Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. 2021 , 147, 2407-2420	8
882	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. 2021 , 26, 3363-3373	20
881	Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis. 2021 , 11, 641878	4
880	Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. 2021 , 26, 232-242	1
879	Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients?. 2021 , 22, 1167-1177	1
878	Systematic evaluation of the 'efficacy-effectiveness gap' in the treatment of depression with venlafaxine and duloxetine. 2021 , 144, 113-124	3

877	Cortical structural differences in major depressive disorder correlate with cell type-specific transcriptional signatures. 2021 , 12, 1647	21
876	Efficacy and acceptability of different interventions for acrophobia: A network meta-analysis of randomised controlled trials. 2021 , 282, 786-794	6
875	Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. 2021 , 16, e0249409	9
874	Conditional power of antidepressant network meta-analysis. 2021 , 21, 129	
873	Opposite genotype-specific effects of serotonergic treatments on Pavlovian Conditioned Approach in mice of two inbred strains C57 BL/6J and DBA/2J. 2021 , 32, 392-403	1
872	Anti-TNF- α Compounds as a Treatment for Depression. 2021 , 26,	5
871	Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective. 2021 , 12, 584416	3
870	Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. 2021 , 4, CD013495	12
869	Immediate and short-term efficacy of suicide-targeted interventions in suicidal individuals: A systematic review. 2021 , 22, 670-685	2
868	Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.	1
867	Evaluation of Switch-to-Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real-World Retrospective Cohort Study. 2021 , 110, 443-451	2
866	The -rs25531 Haplotype and Chronic Stress Moderate the Association Between Acute Stress and Internalizing Mental Disorders Among HIV+ Children and Adolescents in Uganda. 2021 , 12, 649055	1
865	Effects of learning and escitalopram administration on serum BDNF levels, a randomised placebo-controlled trial.	
864	[COPD, anxiety-depression and cognitive disorders: Does inflammation play a major role?]. 2021 , 38, 357-371	3
863	Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. 2021 , 285, 112-119	4
862	Antidepressants and Risk of Sudden Cardiac Death: A Network Meta-Analysis and Systematic Review. 2021 , 9,	2
861	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. 2021 , 43, 189-202	9
860	The primary care assessment and research of a telephone intervention for neuropsychiatric conditions with education and resources study: Design, rationale, and sample of the PARTNERS randomized controlled trial. 2021 , 103, 106284	1

859	First-in-human safety, tolerability, and pharmacokinetics of amoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study. 2021 , 159, 105724	0
858	Suspected Agomelatine-induced restless legs syndrome: a case report. 2021 , 21, 180	1
857	Comparative Efficacy and Acceptability of Psychotherapies for Self-harm and Suicidal Behavior Among Children and Adolescents: A Systematic Review and Network Meta-analysis. 2021 , 4, e216614	5
856	Machine Learning-Based Personalized Pharmacological Treatment for Depressive Disorder: A Target Trial Emulation Study (Preprint).	
855	Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression. 2021 , 38, 451-467	1
854	Comorbid Chronic Pain and Depression: Shared Risk Factors and Differential Antidepressant Effectiveness. 2021 , 12, 643609	13
853	Antidepressants for pain management in adults with chronic pain: a network meta-analysis.	78
852	Evidence of an antidepressant-like effect of xylopic acid mediated by serotonergic mechanisms. 2021 , 238, 2105-2120	0
851	Trial of Psilocybin versus Escitalopram for Depression. 2021 , 384, 1402-1411	152
850	Identification of the Ingredients and Mechanisms of Curcumae Radix for Depression Based on Network Pharmacology and Molecular Docking. 2021 , 16, 1934578X2110166	0
849	A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. 2021 , 35, 992-1002	1
848	Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses. 2021 , 10, 154	2
847	Antidepressant prescriptions have not fully reflected evolving evidence from cumulative network meta-analyses and guideline recommendations. 2021 , 133, 14-23	1
846	Functional impairment-based segmentation of anterior cingulate cortex in depression and its relationship with treatment effects. 2021 , 42, 4035-4047	1
845	Pharmacogenetics of fluoxetine. 2021 , 1, 93-101	
844	The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder. 2021 , 287, 327-333	2
843	Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. 2021 , 144, 110402	2
842	Use of Medications in Suicide Prevention. 2021 , 149-170	

841	COVID-19: Where is the treatment?. 2021 , 12, 309-322	0
840	Partial Personalization of Medical Treatment Decisions: Adverse Effects and Possible Solutions. 2022 , 42, 8-16	
839	Effect of SSRI discontinuation on anxiety-like behaviours in mice.	
838	Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. 2021 , 20, 283-293	24
837	Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. 2021 , 15, 674273	8
836	Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. 2021 , 19, 262-270	6
835	The Telepsychiatry Operational Guidelines 2020 in India: a welcome step. 2021 , 18, E12	0
834	Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression. 2021 , 22,	5
833	Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine. 2021 , 12, 641491	4
832	Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. 2021 , 78, 490-497	8
831	Palliative Medicine: A Holistic Framework for Compassionate Care. 2021 , 24, 644-645	
830	Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design. 2021 , 17, 1459-1468	1
829	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. 2021 , 22, 561-628	3
828	Pharmacological and psychological interventions for depression in people with tuberculosis.	78
827	Tool to assess risk of bias due to missing evidence in network meta-analysis (ROB-MEN): elaboration and examples.	0
826	Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors. 2021 , 29, 392-398	1
825	Neurostimulation Methods in the Treatment of Depression: A Comparison of rTMS, tDCS, and Venlafaxine Using a Pooled Analysis of Two Studies. 2021 , 17, 1713-1722	1
824	Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression. 2021 , 287, 54-68	8

823	Ketamine and the Future of Rapid-Acting Antidepressants. 2021 , 17, 207-231	8
822	Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu) impairs postsynaptic plasticity and modulates affective behaviors. 2021 , 46, 2148-2157	2
821	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. 2021 , 20, 244-275	12
820	Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis. 2021 , 12, 649472	6
819	Blood cytokines differentiate bipolar disorder and major depressive disorder during a major depressive episode: Initial discovery and independent sample replication. 2021 , 13, 100232	3
818	Magnetic resonance imaging in mood disorders: a bibliometric analysis from 1999 to 2020. 2021 , 9, 241-254	
817	Where old is gold again: antidepressants in Nepal, 1961â2021. 1	
816	Serotonin Reuptake Inhibitors and the Gut Microbiome: Significance of the Gut Microbiome in Relation to Mechanism of Action, Treatment Response, Side Effects, and Tachyphylaxis. 2021 , 12, 682868	2
815	Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis. 2021 , 36, e2801	3
814	From accurate diagnosis to targeted therapy: depression in general medical practice. 2021 , 13, 53-58	
813	Deletion of the clock gene Period2 (Per2) in glial cells alters mood-related behavior in mice. 2021 , 11, 12242	4
812	Assessment of early exaggerated treatment effects in orthodontic interventions using cumulative meta-analysis. 2021 , 43, 601-605	0
811	Hybrid Systematic Review and Network Meta-Analysis of Randomized Controlled Trials of Interventions for Depressive Symptoms in Patients With Coronary Artery Disease. 2021 , 83, 423-431	4
810	DNA methylation in stress and depression: from biomarker to therapeutics. 2021 , 33, 217-241	0
809	Manganese-Catalyzed Anti-Markovnikov Hydroamination of Allyl Alcohols via Hydrogen-Borrowing Catalysis. 2021 , 11, 7060-7069	15
808	Duloxetine versus 'active' placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. 2021 , 10, 171	1
807	CYP2C19 polymorphisms are associated with severity of depression at initial evaluation and after the treatment independently of the prescribed medications: 4 weeks prospective study. 2021 , 31, 177-185	1
806	Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. 2021 , 46, 1821-1829	5

805	Magnetic seizure therapy for treatment-resistant depression. 2021 , 6, CD013528	1
804	A Molecular Iron-Based System for Divergent Bond Activation: Controlling the Reactivity of Aldehydes. 2021 , 11, 7176-7185	11
803	Visualizing Patterns of Medication Switching Among Major Depressive Patients with Various Stability and Difficulty to Treatments. 2021 , 17, 1953-1963	0
802	Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analyses. 2021 , 134, 95-102	7
801	Depression scores improve with continuous positive airway pressure in specialized sleep clinics: real-world data. 2021 , 17, 1201-1209	0
800	Depression in multiple sclerosis: Is one approach for its management enough?. 2021 , 51, 102904	5
799	Antidepressant-like effect of dehydrozingerone from Zingiber officinale by elevating monoamines in brain: in silico and in vivo studies. 2021 , 73, 1273-1286	1
798	Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. 2021 , 18, e1003664	3
797	Reduced Anxiety Following Mindfulness and Adaptive Working Memory Training in Women with Breast Cancer. 2021 , 12, 1928-1939	
796	Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry. 2021 , 30, 1258-1268	7
795	Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder. 2021 , 31, 186-193	0
794	Psychopharmacology and Neurotherapeutics. 2021 , 342-388	
793	Disorders Related to Stress and Trauma. 2021 , 166-178	
792	Early onset of depression and treatment outcome in patients with major depressive disorder. 2021 , 139, 150-158	3
791	Knockout of NPFFR2 Prevents LPS-Induced Depressive-Like Responses in Mice. 2021 , 22,	2
790	Hippocampal alpha-synuclein mediates depressive-like behaviors. 2021 , 95, 226-237	0
789	Acupuncture Treatment for Social Defeat Stress. 2021 , 15, 685433	0
788	Feeding and Eating Disorders. 2021 , 289-317	

787	Health Policy and Population Health in Behavioral Health Care in the United States. 2021 , 473-485	
786	Mental health stigma: the role of dualism, uncertainty, causation and treatability. 2021 , 34, e100498	1
785	Comparative Efficacy and Acceptability of Anti-inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis. 2021 , 12, 691200	4
784	Psychosocial Interventions. 2021 , 389-414	
783	Mechanisms and Treatment of Late-Life Depression. 2021 , 19, 340-354	0
782	The Risk of Overdose With Concomitant Use of Z-Drugs and Prescription Opioids: A Population-Based Cohort Study. 2021 , 178, 643-650	3
781	Allopregnanolone in mood disorders: Mechanism and therapeutic development. 2021 , 169, 105682	5
780	Randomized, Placebo-controlled, Antidepressant Treatment of Patients with Major Depressive Disorder: Changes in Glomerular Filtration Rate. 2021 , 27-28, 100083	
779	Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies. 2021 , 12, 702617	4
778	Neurocognitive Disorders. 2021 , 263-288	
777	Proof of concept study to develop a novel connectivity-based electric-field modelling approach for individualized targeting of transcranial magnetic stimulation treatment. 2021 ,	1
776	Introduction to the Patient Interview. 2021 , 38-69	
775	Global Health and Mental Health Care Delivery in Low-Resource Settings. 2021 , 486-496	
774	Diet, Sleep, and Mental Health: Insights from the UK Biobank Study. 2021 , 13,	4
773	Does antidepressant treatment response depend on specific symptoms of depression? A multi-trial study. 2021 , 5, 100153	
772	Determining maximal achievable effect sizes of antidepressant therapies in placebo-controlled trials. 2021 , 144, 300-309	
771	Personality Disorders. 2021 , 233-262	
770	Anxiety Disorders. 2021 , 128-145	

- 769 Child Psychiatry and Neurodevelopmental Disorders. **2021**, 318-328
- 768 Mood Disorders. **2021**, 70-101
- 767 Psychiatry of Gender and Sexuality. **2021**, 448-472
- 766 Obsessive-Compulsive and Related Disorders. **2021**, 146-165
- 765 Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders. **2021**, 16, e0255192 2
- 764 Disrupting the α nAChR-NR2A protein complex exerts antidepressant-like effects. **2021**, 14, 107 1
- 763 The efficacy of Tuina with herbal ointment for patients with post-stroke depression: study protocol for a randomized controlled trial. **2021**, 22, 504 1
- 762 Index. **2021**, 497-512
- 761 Substance Use Disorders. **2021**, 179-232
- 760 Introduction to Psychiatry: Preclinical Foundations and Clinical Essentials. **2021**,
- 759 Sleep Disorders. **2021**, 329-341
- 758 Associations Between Antidepressant Use and Advanced Diabetes Outcomes in Patients with Depression and Diabetes Mellitus. **2021**, 106, e5136-e5146 1
- 757 Early Optimistic Effect in Periodontology and Implant Dentistry Trials. **2021**, 220345211025242 1
- 756 Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk?. **2021**, 290, 254-260 0
- 755 Psychiatric Evaluation in the Medical Setting. **2021**, 415-447
- 754 Introduction. **2021**, 1-8
- 753 Schizophrenia Spectrum and Other Psychotic Disorders. **2021**, 102-127
- 752 Clinical Neuroscience. **2021**, 9-37

751	Epigenetics: A missing link between early life stress and depression. 2021 , 109, 110231	8
750	Decreased thalamo-cortico connectivity during an implicit sequence motor learning task and 7 days escitalopram intake. 2021 , 11, 15060	1
749	The Potential Role of Serotonergic Hallucinogens in Depression Treatment. 2021 , 11,	0
748	Circadian depression: A mood disorder phenotype. 2021 , 126, 79-101	11
747	SITAgliptin for Depressive Symptoms in Type 2 Diabetes: A Feasibility Randomized Controlled Trial. 2021 , 83, 913-923	1
746	Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology. 2021 , 9,	1
745	Efficacy of Different Interventions to Reduce Pre- or Perioperative Blood Transfusion Rate in Patients with Colorectal Cancer: A Network Meta-Analysis of Randomized Controlled Trials. 2021 , 28, 3214-3226	0
744	Non-superiority of zuranolone (SAGE-217) at the longer-term. 2021 , 291, 329-330	2
743	Efficacy of Chinese patent medicine for primary osteoporosis: A network meta-analysis. 2021 , 44, 101419	5
742	Depression(therapie) – ein Feld der Integration?. 2021 , 22, 17-23	
741	Revisiting Treatment Options for Depressed Patients with Generalised Anxiety Disorder. 2021 , 38, 61-68	2
740	Shaping Future Doctors' Minds: Effects of Biological and Social Models on Medical Students' Views on Depression. 2021 , 1	0
739	Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. 2021 , 14, 1317-1319	3
738	Antidepressiva – wirksam und gut verträglich?. 2021 , 22, 44-48	
737	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. 2021 , 11, 439	1
736	Fatigue as the Chief Complaint. 2021 , 118, 566-576	0
735	Tricyclic antidepressants versus 'active placebo', placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. 2021 , 10, 227	2
734	Pharmakotherapie der Depression – neue Erkenntnisse und neue Strategien. 2021 , 22, 49-53	1

733	Efficacy and tolerability of in treating patients with the diagnosis of depression: a systematic review of randomized controlled trials. 2021 ,	
732	An Experimental Medicine Investigation of the Effects of Subacute Pramipexole Treatment on Emotional Information Processing in Healthy Volunteers. 2021 , 14,	3
731	Management of Phantom Limb Pain after Amputation by Adjunctive Use of Mianserin in a Diabetic Case on Hemodialysis: A Case Report. 2021 , 24, 1268-1269	0
730	Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis. 2021 , 292, 416-423	5
729	Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Meta-Analysis of Pharmacotherapy. 2021 , 3, 123-140	0
728	Brain Metabolic Profile after Intranasal vs. Intraperitoneal Clomipramine Treatment in Rats with Ultrasound Model of Depression. 2021 , 22,	1
727	Probiotic Bacteria in the Correction of Depression Symptoms, Their Active Genes and Proteins. 2021 , 57, 1017-1025	1
726	Psychédliques, psychothérapie et symbolisation : une revue de littérature dans le champ de la dépression. 2021 , 86, 591-616	1
725	New Molecular Targets for Antidepressant Drugs. 2021 , 14,	4
724	Learning from the global response to COVID-19 to accelerate innovation in mental health trials. 2021 , 20, 358-359	1
723	Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine. 2022 , 296, 258-264	1
722	The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review. 2021 ,	4
721	Behavioral and neurochemical effects of folic acid in a mouse model of depression induced by TNF- α 2021 , 414, 113512	2
720	Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany. 2021 , 25, 393-402	1
719	Use of Sertraline in Hemodialysis Patients. 2021 , 57,	2
718	Not sad enough for a depression trial? A systematic review of depression measures and cut points in clinical trial registrations. 2021 , 292, 36-44	4
717	An evolutionary approach to grief-related rumination: Construction and validation of the Bereavement Analytical Rumination Questionnaire. 2021 , 42, 441-452	3
716	Crystalline Forms of Trazodone Dihydrates. 2021 , 26,	

715	Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. 2021 , 12, 729800	3
714	Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. 2021 , 52, 2802-2808	5
713	Antidepressant use in low- middle- and high-income countries: a World Mental Health Surveys report. 1-9	1
712	Impact of Inosine on Chronic Unpredictable Mild Stress-Induced Depressive and Anxiety-Like Behaviors With the Alteration of Gut Microbiota. 2021 , 11, 697640	2
711	Efficacy of pharmacologic treatment in tinnitus patients without specific or treatable origin: A network meta-analysis of randomised controlled trials. 2021 , 39, 101080	4
710	Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. 2021 , 20, 387-396	7
709	Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial. 2021 , 11, 18911	1
708	Predictors of relapse following a stepwise psychopharmacotherapy regime in patients with depressive disorders. 2021 , 293, 109-116	1
707	Association of the neutrophil to lymphocyte ratio and white blood cell count with response to pharmacotherapy in unipolar psychotic depression: An exploratory analysis. 2021 , 16, 100319	
706	Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression. 2021 , 16, 100331	3
705	[Treatments for depression in consultation-liaison psychiatry: From theory to practice]. 2021 , 42, 694-706	
704	Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the Netherlands. 2021 , 21, 481	1
703	Transdiagnostic biomarker approaches to mental health disorders: Consideration of symptom complexity, comorbidity and context. 2021 , 16, 100303	3
702	Rating, berating or overrating antidepressant efficacy? The case of the Hamilton depression rating scale. 2021 , 52, 12-14	1
701	Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials. 2021 , 143, 230-238	4
700	Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease. 2021 , 227, 107873	3
699	Estimating the global treatment rates for depression: A systematic review and meta-analysis. 2021 , 295, 1234-1242	8
698	Short term impact of antidepressants on the cardinal symptoms of depression in OSA patients with comorbid MDD who are APAP-adherent: A retrospective study in a veteran population.. 2021 , 6, 100236	

- 697 Protective effect of mirtazapine against acetic acid-induced ulcerative colitis in rats: Role of NLRP3 inflammasome pathway. **2021**, 101, 108174 3
- 696 Neuroimaging Biomarkers in Pediatric Mood Disorders. **2021**, 28-38
- 695 Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus. **2021**, 7-15
- 694 The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression. **2020**, 11, 599588 0
- 693 Linking citalopram, serotonin reuptake inhibitors, and depressed pregnant women. **2021**, 325-336
- 692 Agomelatine: Profile and applications to depression. **2021**, 301-308
- 691 Erector Spinae Plane Catheters: A Novel Intervention in Total Hip Arthroplasty. **2021**, 22, 2409-2410
- 690 Analysis of Functional Brain Network in MDD Based on Improved Empirical Mode Decomposition With Resting State EEG Data. **2021**, 29, 1546-1556 1
- 689 Pharmacological assistance for psychotherapy. **2021**, 1, 100017
- 688 Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. **2021**, 46, 1272-1282 4
- 687 Role of age, gender and marital status in prognosis for adults with depression: An individual patient data meta-analysis. **2021**, 30, e42 11
- 686 Forest therapy can prevent and treat depression: Evidence from meta-analyses. **2021**, 57, 126943 12
- 685 Physical activity, exercise, and mental disorders: it is time to move on. **2021**, 43, 177-184 3
- 684 Prevalence of patients treated with antidepressant medicine in Greenland and Denmark: a cross-sectional study. **2021**, 80, 1912540 1
- 683 The Application of a Machine Learning-Based Brain Magnetic Resonance Imaging Approach in Major Depression. **2021**, 1305, 57-69 2
- 682 Putative effects of cannabidiol in depression and synaptic plasticity. **2021**, 459-467 1
- 681 Functional Connectome in Bipolar Disorder. **2021**, 59-82
- 680 Resting-State Functional Connectivity in Unipolar Depression. **2021**, 49-58

679	Imaging Genetic and Epigenetic Markers in Mood Disorders. 2021 , 135-150	
678	fMRI Neurofeedback as Treatment for Depression. 2021 , 151-165	
677	Serotonin Reuptake Inhibitors: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline. 2021 , 1-13	0
676	Rigor and reproducibility training for first year medical students in research pathways. 2021 , 14, 1026-1036	2
675	Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury. 2021 , 44, 102-162	1
674	Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. 2021 , 238, 341-354	19
673	Pharmacy-based management for depression in adults.	3
672	Antidepressants: Indications, Contraindications, Interactions, and Side Effects. 2020 , 1-38	2
671	Psychopharmaka. 2018 , 733-761	3
670	Psychopharmaka. 2019 , 927-959	2
669	Chemistry of Neurochemicals: Psychopharmaceuticals and Neuropeptides. 2020 , 41-70	1
668	Standardized Treatment Strategy for Depressive Disorder. 2019 , 1180, 193-199	8
667	Clinical patterns differentially predict response to transcranial direct current stimulation (tDCS) and escitalopram in major depression: A machine learning analysis of the ELECT-TDCS study. 2020 , 265, 460-467	15
666	Efficacy and cost-effectiveness of intensive short-term dynamic psychotherapy for treatment resistant depression: 18-Month follow-up of the Halifax depression trial. 2020 , 273, 194-202	7
665	Predicting treatment effects in unipolar depression: A meta-review. 2020 , 212, 107557	10
664	Interest of pharmacoepidemiology for the study of psychotropic drugs. 2019 , 74, 239-244	2
663	Therapy and prevention for mental health: What if mental diseases are mostly not brain disorders?. 2019 , 42, e13	5
662	Levers and barriers to success in the use of translational neuroscience for the prevention and treatment of mental health and promotion of well-being across the lifespan. 2020 , 129, 38-48	6

661	Estimating outcome probabilities from early symptom changes in cognitive therapy for recurrent depression. 2019 , 87, 510-520	2
660	The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial. 2021 , 46, 1307-1314	11
659	Vitamin E for the management of major depressive disorder: possible role of the anti-inflammatory and antioxidant systems. 2020 , 1-15	13
658	Comorbid chronic pain and depression: Shared risk factors and differential antidepressant effectiveness.	1
657	Accounting for small-study effects using a bivariate trim and fill meta-analysis procedure.	1
656	Assessing Confidence in the Results of Network Meta-Analysis (Cinema).	16
655	Differential Treatment Benefit Prediction For Treatment Selection in Depression: A Deep Learning Analysis of STAR*D and CO-MED Data.	2
654	Comparative effectiveness of physical exercise interventions for chronic non-specific neck pain: a systematic review with network meta-analysis of 40 randomised controlled trials. 2020 ,	6
653	Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men. 2019 , 4,	2
652	Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. 2020 , 18, 443-455	6
651	On the treatment effect heterogeneity of antidepressants in major depression: A Bayesian meta-analysis and simulation study. 2020 , 15, e0241497	9
650	Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain. 2020 , 15, e0243057	1
649	Antidepressant therapy in patients with cardiovascular diseases. 2019 , 11, 131-140	6
648	The use of vortioxetine for depression in patients with Parkinson's disease in the early and advanced stages of the disease. 2020 , 12, 40-45	1
647	Exercise prescription for people with mental illness: an evaluation of mental health professionals' knowledge, beliefs, barriers, and behaviors. 2020 , 42, 271-277	7
646	Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. 2020 , 42, 317-321	9
645	[Efficacy and tolerability of contemporary antidepressants: results of network meta-analyses and Russian experience]. 2018 , 118, 109-117	7
644	False Beliefs in Academic Psychiatry: The Case of Antidepressant Drugs. 2018 , 20, 6-16	5

643	Fluoxetine in stroke (FOCUS) trial-reasons to be cheerful about antidepressants in stroke?. 2019 , 7, S131	2
642	The Effects of Probiotics and Prebiotics on Mental Disorders: A Review on Depression, Anxiety, Alzheimer, and Autism Spectrum Disorders. 2020 , 21, 555-565	42
641	Repetitive Transcranial Magnetic Stimulation Combined with Antidepressants for the First Episode of Major Depressive Disorder. 2020 , 18, 852-860	4
640	Supported Internet-Delivered Cognitive Behavior Treatment for Adults with Severe Depressive Symptoms: A Secondary Analysis. 2018 , 5, e10204	10
639	Feasibility of a Therapist-Supported, Mobile Phone-Delivered Online Intervention for Depression: Longitudinal Observational Study. 2019 , 3, e11509	12
638	Long-Term Outcomes of a Therapist-Supported, Smartphone-Based Intervention for Elevated Symptoms of Depression and Anxiety: Quasiexperimental, Pre-Postintervention Study. 2019 , 7, e14284	18
637	Three Decades of Internet- and Computer-Based Interventions for the Treatment of Depression: Protocol for a Systematic Review and Meta-Analysis. 2020 , 9, e14860	5
636	Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. 2020 , 24, 1-94	6
635	Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT. 2019 , 7, 1-108	3
634	Chaperone Sigma1R and Antidepressant Effect. 2020 , 21,	6
633	Matching depression management to severity prognosis in primary care: results of the Target-D randomised controlled trial. 2021 , 71, e85-e94	6
632	Efficacy of GG in treatment of acute pediatric diarrhea: A systematic review with meta-analysis. 2019 , 25, 4999-5016	30
631	Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis. 2019 , 34, 966-973	25
630	Treatment-Resistant Depression: Identification and Treatment Strategies. 2018 , 56, 11-15	4
629	Role of Prophylactic Magnesium Supplementation in Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting: a Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials. 2019 , 12, 2154	7
628	Meaning in Life and Its Relationship With Physical, Mental, and Cognitive Functioning: A Study of 1,042 Community-Dwelling Adults Across the Lifespan. 2019 , 81,	18
627	5-HTTLPR and >T polymorphisms and response to yoga-based lifestyle intervention in major depressive disorder: A randomized active-controlled trial. 2018 , 60, 410-426	5
626	Differences of Plasma Levels of Tryptophan, Serotonin, 5-Hydroxyindole Acetic Acid, and Kynurenine between Healthy People and Patients of Major Monopolar Depression at Various Age and Gender. 2020 , 11, 431-441	3

625	Symptom-based selection of antidepressants. 2020 , 63, 216-226	1
624	Chemical and structural investigation of the paroxetine-human serotonin transporter complex. 2020 , 9,	19
623	Association of sleep among 30 antidepressants: a population-wide adverse drug reaction study, 2004-2019. 2020 , 8, e8748	4
622	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. 2018 , 16, 469-480	15
621	Frequency and Predictors of Potential Drug Interactions among Psychiatry Outpatients on Treatment with Antidepressant Medications. 2021 , 14, 1209-1218	
620	Inflammation and depression in young people: a systematic review and proposed inflammatory pathways. 2021 ,	2
619	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis.. 2021 , 51, 2742-2751	3
618	Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19. 2021 , 43, 633-643	1
617	Integrated analysis of the chemical-material basis and molecular mechanisms for the classic herbal formula of Lily Bulb and Rehmannia Decoction in alleviating depression. 2021 , 16, 107	1
616	Effect of regulatory interventions on agomelatine use in Spain: A multiple intervention time-series analysis in a nationwide electronic healthcare record database. 2021 ,	
615	Comparing the evidential strength for psychotropic drugs: a Bayesian meta-analysis. 2021 , 1-10	
614	Pharmacogenomics: A road ahead for precision medicine in psychiatry. 2021 ,	1
613	Addressing anhedonia to increase depression treatment engagement. 2021 ,	1
612	Short Term Caloric Restriction and Biofeedback Enhance Psychological Wellbeing and Reduce Overweight in Healthy Women. 2021 , 11,	1
611	Exploring the Impact of Flavonoids on Symptoms of Depression: A Systematic Review and Meta-Analysis. 2021 , 10,	2
610	Understanding Delivery of Collectively Built Protocols in an Online Health Community for Discontinuation of Psychiatric Drugs. 2021 , 5, 1-29	1
609	Antidepressant treatment trajectories and suicide attempt among Australians aged 45 years and older: A population study using individual prescription data. 2021 ,	0
608	Sertraline for Functional Recovery After Acute Ischemic Stroke: A Prospective Observational Study. 2021 , 12, 734170	0

607	Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. 2021 , 1	1
606	Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary. 2021 , 19, 751-772	5
605	Antidepressants: Myths, facts and perspectives. 2017 , 67, 291-301	
604	Efficacy of antidepressants: Ten years of meta-analysis Kiril and associate. 2017 , 49, 91-106	
603	Brain teasers: Psychiatry and allied sciences quiz. 2018 , 2, 163	
602	[Antidepressants: the goals and possibilities of therapy]. 2018 , 118, 120-124	
601	The most effective antidepressants for adults revealed in major review.	
600	Factors associated with medication errors in the psychiatric ward of Razi Hospital in Tabriz: Perspectives of nurses. 2018 , 8, 1-8	
599	Approaching to the Essence of Major Depressive Disorder. 2018 , 15-17	
598	Approaches to therapy for depressions in neurology: prospects for the use of agomelatine. 2018 , 10, 101-110	5
597	Pharmacologie des antidepressants. 2019 , 185-199	
596	[Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability]. 2019 , 119, 154-161	0
595	Antidepressiva. 2019 , 1-208	2
594	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. 2019 , 1-119	
593	Neurocognitive Mechanisms for Detecting Early Phase of Depressive Disorder. 2019 , 165-198	
592	A phenome-wide association and Mendelian Randomisation study of polygenic risk for depression in UK Biobank.	
591	Long-Term Outcomes of a Therapist-Supported, Smartphone-Based Intervention for Elevated Symptoms of Depression and Anxiety: Quasiexperimental, Pre-Postintervention Study (Preprint).	1
590	Depressive Disorders. 2019 ,	0

- 589 [Antidepressants and Suicidality: A Contradiction?]. **2019**, 108, 487-494 0
- 588 Depressive Disorders. **2019**,
- 587 Effects of Repeated Treatment with Monoamine-Transporter-Inhibitor Antidepressants on Pain-Related Depression of Intracranial Self-Stimulation in Rats.
- 586 Are modern neuromodulation therapies too precise?. **2019**, 17-18, 1-3
- 585 Randomized Controlled Trials and the Efficacy of Psychotropic Medications. **2020**, 1-56
- 584 Redefining Therapeutic Outcomes of Depression Treatment. **2019**, 5, 1-8 1
- 583 Guidelines for the Use of Parkinsonian Drugs in Canada. **2020**, 1-9
- 582 Comparison of Age and Gender Differences of Tryptophan Metabolites in Patients of Major Monopolar and Bipolar Depression. **2020**, 11, 172-185 3
- 581 Mirtazapine and Depressions. **2020**, 1-29
- 580 The Use of Extracorporeal Life Support in a Patient Suffering from Venlafaxine Intoxication. A Case Report. **2020**, 6, 120-123 2
- 579 Challenges of Mood Disorders Care. **2020**, 18, 205-207
- 578 Sportliche Aktivität und psychische Erkrankungen. **2020**, 14, 255-271
- 577 Modulation of premotor cortex response to sequence motor learning during escitalopram-intake.
- 576 Toward a New Model of Understanding, Preventing, and Treating Adolescent Depression Focusing on Exhaustion and Stress. **2020**, 11, 412 3
- 575 Comprehensive exploration of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders.
- 574 Clinical Topics in Old Age Psychiatry. **2020**,
- 573 What have antidepressants been tested for? A systematic review. **2020**, 31, 157-163
- 572 Real-time fMRI neurofeedback training as a neurorehabilitation approach on depressive disorders: A systematic review of randomized control trials.

571	Different Effects of Fluoxetine and Paroxetine Combined with Vitamin D3 in Ovariectomized Rats Exposed to Unpredictable Stress. 2020 , 8, 29-46	
570	POSSIBLE COMPLICATIONS OF ANTIDEPRESSANTS AND THEIR CORRECTION. 2020 , 73-80	
569	Low-Frequency Sonophoresis as an Active Approach to Potentiate the Transdermal Delivery of Agomelatine-Loaded Novasomes: Design, Optimization, and Pharmacokinetic Profiling in Rabbits. 2021 , 22, 261	0
568	Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects. 2021 , 22,	1
567	Treatment-Resistant Depression: Deep Brain Stimulation. 2020 , 417-432	1
566	Bupropion and Depressions. 2020 , 1-10	
565	Deletion of the Clock Gene Period2 (Per2) in Glial Cells Alters Mood-Related Behavior in Mice.	
564	Proof of concept study to develop a novel connectivity-based electric-field modelling approach for individualized targeting of transcranial magnetic stimulation treatment.	0
563	Association between Antidepressant Treatment during Pregnancy and Postpartum Self-Harm Ideation in Women with Psychiatric Disorders: A Cross-Sectional, Multinational Study. 2020 , 18,	0
562	Molecular Imaging of Depressive Disorders. 2021 , 85-207	0
561	Depression and Anxiety in College Students. 2021 , 57-76	
560	Treatment options for pharmacoresistant depression in routine clinical practice. 2020 , 21, 124-127	
559	Clinical Neuropharmacology. 2021 , 103-152	
558	Proprioceptive training on the recovery of total knee arthroplasty patients: A meta-analysis protocol of randomized controlled trial. 2020 , 99, e23757	
557	Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study. 2022 , 296, 609-615	0
556	Affective Disorders. 2021 ,	
555	A UPLC-MS/MS Assay for Simultaneous Determination of Two Antipsychotics and Two Antidepressants in Human Plasma and Its Application in Clinic. 2020 , 21, 60-69	0
554	Psychopharmaka. 2020 , 781-814	4

- 553 Positive Interventions in Depression. **2020**, 103-108
- 552 [Pandemic COVID-19 and mental disorders international experience and therapeutic approaches]. **2020**, 120, 121-129 4
- 551 Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression. **2020**, 10, 2045125320981498 0
- 550 Affektive Störungen am Beispiel der unipolaren Depression. **2020**, 297-325
- 549 Unipolar depression. **2020**, 613-631
- 548 First generation antihistaminic drugs used in the treatment of insomnia – superstitions and evidence. **2020**, 36, 33-40
- 547 Technological Interventions for Depression. **2020**,
- 546 Embodying Hot Cognitive Vulnerability to Emotional Disorders. **2020**, 1-14
- 545 Dire dâhdignit'mlancolique, pure douleur dâxister et peine auto-thfapeutique. **2020**, Numfo565, 17
- 544 Psychopharmacology: A Brief Overview of Its History. **2020**, 1-41
- 543 Pharmacogenetics of antidepressants: A step to individualized therapy. **2020**, 1, 13-20
- 542 Studien bei Kindern und Jugendlichen. **2020**, 1-12
- 541 Efficacy and Acceptability Comparisons of Cognitive Behavior Therapy, Drugs, and Their Combination for Panic Disorder in Adults: a Network Meta-analysis.
- 540 Chemical and structural investigation of the paroxetine-human serotonin transporter complex. 1
- 539 On the treatment effect heterogeneity of antidepressants in major depression. A Bayesian meta-analysis. 3
- 538 Generating interpretable predictions about antidepressant treatment stability using supervised topic models. 0
- 537 Systematic Review and Network Meta-Analysis of Anodal tDCS Effects on Verbal Episodic Memory. **2020**, 228, 3-13 2
- 536 PreTA: A network meta-analysis ranking metric measuring the probability of being preferable than the average treatment.

535	The Effects and Mechanisms of Exercise on the Treatment of Depression. 2021 , 12, 705559	6
534	Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial. 2021 , 11, 559	5
533	Understanding genetic risk factors for common side effects of antidepressant medications. 2021 , 1,	2
532	Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study. 2021 , 41, 1055-1066	
531	Efficacy of a Multimodal Online Lifestyle Intervention for Depressive Symptoms and Quality of Life in Individuals With a History of Major Depressive Disorder. 2020 , 12, e9061	0
530	The Handbook of Wellness Medicine. 2020 ,	2
529	Nutraceuticals and Wellness. 2020 , 292-301	1
528	Rezidivprophylaxe der Depression: Pharmakologie. 2020 , 14, 487-498	
527	Methylome-wide association study of antidepressant use in Generation Scotland and the Netherlands Twin Register implicates the innate immune system.	0
526	Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder. 2021 , 41, 62-66	3
525	PALM: Patient-centered Treatment Ranking via Large-scale Multivariate Network Meta-analysis.	
524	Antidepressiva. 2021 , 1-186	
523	Psychiatric Prescribing Patterns for Depression Treatment in an Outpatient Depression Clinic. 2020 , 50, 28-34	
522	A Social Media Study on the Effects of Psychiatric Medication Use. 2019 , 13, 440-451	8
521	Essential Oils and Health. 2020 , 93, 291-305	9
520	Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury: Clinical Practice Guideline for Healthcare Providers. 2021 , 27, 152-224	2
519	Consistently Modest Antidepressant Effects in Clinical Trials: the Role of Regulatory Requirements. 2021 , 51, 79-108	
518	Korean Medication Algorithm Project for Depressive Disorder 2021 (V): Antidepressant Choices According to Safety, Adverse Effect, Comorbid Physical Illnesses and Clinical Definition of Treatment Resistant Depression. 2021 , 60, 267	

- 517 Agomelatine and Depressions. **2021**, 1-11
- 516 Web-Based Psychotherapy and Exercise Interventions for Depressive and Anxiety Disorders. **2022**, 93-114
- 515 Lipoic acid prevents mirtazapine-induced weight gain in mice without impairs its antidepressant-like action in a neuroendocrine model of depression. **2021**, 419, 113667
- 514 Omega-3 fatty acids for depression in adults. **2021**, 11, CD004692 4
- 513 Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. **2021**, 114, 110480 1
- 512 Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment. **2021**, 12, 736318 0
- 511 Efficacy of bio- and neurofeedback for depression: a meta-analysis. **2021**, 1-16 1
- 510 Psychiatry is essential for now but might eventually disappear (although this is unlikely to happen any time soon). **2021**, 10398562211048141
- 509 Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis. **2021**, 1-8 1
- 508 Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT. **2021**, 25, 1-62 0
- 507 Selection of psychotropics in dermatologic practice. 1, 60
- 506 ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis. **2021**, 19, 304 2
- 505 Out-patient triple chronotherapy for the rapid treatment and maintenance of response in depression: feasibility and pilot randomised controlled trial. **2021**, 7, 0
- 504 [Rapid-acting antidepressants-neurobiological mechanisms of action]. **2021**, 1
- 503 From the Second Half of the Twentieth Century to the Early Twenty-First: The Psychopharmacologic Era. **2022**, 237-326
- 502 Die homöopathische Behandlung von Depressionen. **2021**, 266, 4-10
- 501 Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study. **2021**, 8, 1071-1082 6
- 500 The Long Noncoding RNA FEDORA is a Cell-Type- and Sex-Specific Regulator of Depression. 0

499	Trazodone and Depression. 2022 , 1-9	
498	Psychopharmaka. 2021 , 689-725	0
497	Update Psychopharmakotherapie psychischer Erkrankungen im Erwachsenenalter. 1	1
496	Comprehensive exploration of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders.. 2022 , 12, 11	1
495	Pharmacologic Treatment for Perinatal Mental Health Disorders.. 2022 , 139,	0
494	Social and economic factors associated with antidepressant use: Results of a national survey in primary care. 2022 , 8, 100307	0
493	Clinical response to SSRIs relative to cognitive behavioral therapy in depression: a symptom-specific approach.. 2022 , 21, 152-153	0
492	Utilization of healthcare and prescription medicines after non-pharmacological interventions for depression - A 3-year register follow-up of an RCT in primary care.. 2022 , 25, 101658	1
491	More treatment but no less depression: The treatment-prevalence paradox.. 2021 , 91, 102111	7
490	Pigment epithelium-derived factor may induce antidepressant phenotypes in mice by the prefrontal cortex.. 2021 , 136423	0
489	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder.. 2021 , 308, 114354	
488	Comprehending the potential of metallic, lipid, and polymer-based nanocarriers for treatment and management of depression.. 2021 , 153, 105259	1
487	Baseline Anxiety, and Early Anxiety/Depression Improvement in Anxious Depression Predicts Treatment Outcomes with Escitalopram: A CAN-BIND-1 Study Report.. 2021 ,	0
486	Repeated Leg Edema Induced by Trazodone and Mirtazapine in a Patient With Depression With Successful Agomelatine Substitution: A Case Report. 2020 ,	1
485	Depression, Anxiety, and Suicide After Stroke: A Narrative Review of the Best Available Evidence. 2021 , STROKEAHA121035499	4
484	Esketamine for treatment-resistant depression in adults. 2022 , 2022,	
483	[Melatonin: A short clarification for the over-enthusiasts].. 2022 , 38, 89-95	1
482	Psychoactive drugs citalopram and mirtazapine caused oxidative stress and damage of feeding behavior in Daphnia magna.. 2021 , 230, 113147	1

- 481 Antidepressant Treatment-Induced State-Dependent Reconfiguration of Emotion Regulation Networks in Major Depressive Disorder.. **2021**, 12, 771147 0
- 480 Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A CAN-BIND Study.. **2022**, 0
- 479 Current Therapies in Patients With Posterior Semicircular Canal BPPV, a Systematic Review and Network Meta-analysis.. **2022**, 43, 0
- 478 Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study.. **2022**, 1
- 477 Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.. **2022**, 0
- 476 Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis.. **2022**, 42, 2
- 475 Angst, Depression und nichtspezifische (funktionelle) Körperbeschwerden. **2022**, 579-595 0
- 474 Comparative Effectiveness of Transcutaneous Auricular Vagus Nerve Stimulation vs Citalopram for Major Depressive Disorder: A Randomized Trial.. **2021**, 0
- 473 Effects of Mindfulness Meditation Intervention on Depressive Symptoms in Emerging Adults: A Systematic Review and Meta-Analysis.. **2022**, 28, 6-24 1
- 472 Areas of Interest and Social Consideration of Antidepressants on English Tweets: A Natural Language Processing Classification Study.. **2022**, 12, 1
- 471 Risks of Antidepressant induced psychotic events in patients with depression and psychosis. 0
- 470 Initial Severity and Depressive Relapse in Cognitive Behavioral Therapy and Antidepressant Medications: An Individual Patient Data Meta-analysis. 1 0
- 469 Antidepressant Sertraline Is a Broad-Spectrum Inhibitor of Enteroviruses Targeting Viral Entry through Neutralization of Endolysosomal Acidification.. **2022**, 14, 2
- 468 The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.. **2022**, 21, 133-145 16
- 467 Tai Chi and other mind-body interventions for cancer-related fatigue: an updated systematic review and network meta-analyses protocol.. **2022**, 12, e052137 0
- 466 A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder.. **2022**, 1-25 0
- 465 Chronoradiobiology of Breast Cancer: The Time Is Now to Link Circadian Rhythm and Radiation Biology.. **2022**, 23, 1
- 464 Antidepressant-like effects of cinnamamide derivative M2 via D receptors in the mouse medial prefrontal cortex.. **2022**, 0

463	Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.. 2021 ,	4
462	Implementation of personalised medicine policies in mental healthcare: results from a stated preference study in the UK.. 2022 , 8, e40	1
461	The impact of mental health support for the chronically ill on hospital utilisation: Evidence from the UK.. 2021 , 294, 114675	0
460	Associations between education levels and prevalence of depressive symptoms: NHANES (2005-2018).. 2022 , 301, 360-367	0
459	Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran. 2022 , 1-27	
458	Effects of Zuojin Pill (Rhizoma Coptidis and Fructus Evodiae preparation) on the pharmacokinetics and side effects of venlafaxine in humans.. 2022 ,	
457	The interplay between pharmacogenetics, concomitant drugs and blood levels of amitriptyline and its main metabolites.. 2022 ,	0
456	Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis.. 2022 ,	0
455	Meta-Analysis of Positive Psychology Interventions on the Treatment of Depression.. 2022 , 14, e21933	0
454	Vitamin E, Alpha-Tocopherol, and Its Effects on Depression and Anxiety: A Systematic Review and Meta-Analysis.. 2022 , 14,	6
453	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.. 2021 ,	10
452	Rewiring of the Serotonin System in Major Depression.. 2021 , 12, 802581	2
451	Validation of Machine Learning-Based Individualized Treatment for Depressive Disorder Using Target Trial Emulation.. 2021 , 11,	0
450	Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. 2022 , 1, 100104	1
449	Psychosocial Dimension in Older Adults with Cancer and Frailty. 2022 , 71-91	
448	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors.. 2022 , 13, 826138	2
447	Abnormalities of Thalamic Functional Connectivity in Patients with Migraine: A Resting-State fMRI Study.. 2022 , 1	0
446	Serotonin Receptor and Transporter Endocytosis Is an Important Factor in the Cellular Basis of Depression and Anxiety.. 2021 , 15, 804592	

- 445 Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials.. **2022**, 23, 28 ○
- 444 Identifying Environmental Endocrine Disruptors Associated With the Age at Menarche by Integrating a Transcriptome-Wide Association Study With Chemical-Gene-Interaction Analysis.. **2022**, 13, 836527
- 443 Comparative evaluation of psychopharmacotherapy of atypical depression in bipolar and recurrent affective disorder, psychogenic depression. **2022**, 14, 52-59
- 442 Comparative Efficacy of Xianling Gubao Capsules in Improving Bone Mineral Density in Postmenopausal Osteoporosis: A Network Meta-Analysis.. **2022**, 13, 839885 ○
- 441 Suspected suicides and nonfatal suicide attempts involving antidepressants reported to United States poison control centers, 2000-2020.. **2022**, 1-9 1
- 440 A dose-effect network meta-analysis model with application in antidepressants using restricted cubic splines.. **2022**, 9622802211070256 ○
- 439 A Systematic Review of Candidate Genes for Major Depression.. **2022**, 58, ○
- 438 Depressive Erkrankungen in der Hausarztpraxis. **2022**, 03, 37-54
- 437 Answering complex hierarchy questions in network meta-analysis.. **2022**, 22, 47
- 436 Exercise and yoga during pregnancy and their impact on depression: a systematic literature review.. **2022**, 1 ○
- 435 A single oral dose of citalopram increases interoceptive insight in healthy volunteers.. **2022**, 1 1
- 434 Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.. **2022**, e2555 1
- 433 Efficacy of journaling in the management of mental illness: a systematic review and meta-analysis.. **2022**, 10, ○
- 432 Trajectories of Depressive and Anxiety Symptoms Across Pregnancy and Postpartum in Selective Serotonin Reuptake Inhibitor-Treated Women. n/a-n/a ○
- 431 Pharmacological Treatment of Individuals at Familial Risk for Bipolar or Major Depressive Disorders: a Scoping Review. 1
- 430 Comparative Efficacy and Safety of 11 Drugs as Therapies for Adults With Neuropathic Pain After Spinal Cord Injury: A Bayesian Network Analysis Based on 20 Randomized Controlled Trials.. **2022**, 13, 818522 1
- 429 Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy-Case Series.. **2022**, 13, 852042 ○
- 428 Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.. **2022**, ○

427	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: an updated systematic review and meta-analysis.. 2022 , 1-29		1
426	Engaging Patients with Depression in Treatment Continuity.. 2022 , 1		0
425	Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability.. 2022 ,		1
424	Time for united action on depression: a Lancet-World Psychiatric Association Commission.. <i>Lancet, The</i> , 2022 , 399, 957-1022	40	23
423	Beyond Response: Aiming for Quality Remission in Depression.. 2022 , 1		0
422	The gut microbiome and mental health: advances in research and emerging priorities.. 2022 ,		0
421	Mirtazapine in schizophrenia - an undeservedly overlooked option?. 2022 ,		0
420	The Joint Association Between Multiple Dietary Patterns and Depressive Symptoms in Adults Aged 55 and Over in Northern China.. 2022 , 9, 849384		0
419	Senior Residents' Perceived Competence in Evidence-Based Treatments for Major Depressive Disorder.. 2022 , 1		
418	Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.. 2022 ,		0
417	Initiating Antidepressant Medication: What is the Most Important Factor?. 2022 , 1		
416	Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.. 2022 , 13, 824831		2
415	Treatment-Resistant Depression in Portugal: Perspective From Psychiatry Experts.. 2022 , 13, 824919		
414	Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis.. 2022 ,		2
413	Mental Health in Australia: Psychological Distress Reported in Six Consecutive Cross-Sectional National Surveys From 2001 to 2018.. 2022 , 13, 815904		1
412	Quality of clinical practice guidelines for inadequate response to first-line treatment for depression according to AGREE II checklist and comparison of recommendations: a systematic review.. 2022 , 12, e051918		0
411	Inflammation, Lifestyle Factors, and the Microbiome-Gut-Brain Axis: Relevance to Depression and Antidepressant Action.. 2022 ,		2
410	Proprietary Medicines Containing DC. (Chaihu) for Depression: Network Meta-Analysis and Network Pharmacology Prediction.. 2022 , 13, 773537		1

409	Changes in leukocytes and CRP in different stages of major depression.. 2022 , 19, 74	0
408	Deceptive and non-deceptive placebos to reduce sadness: A five-armed experimental study. 2022 , 100349	1
407	Does the evidence support a relationship between higher levels of nut consumption, lower risk of depression, and better mood state in the general population? A systematic review.. 2022 ,	0
406	Brain function mediates the association between low vitamin D and neurocognitive status in female patients with major depressive disorder.. 2022 , 1-14	0
405	Depression After Parkinson's Disease: Treated Differently or Not At All?. 2022 , 8919887221090217	1
404	Effects of the selective serotonin reuptake inhibitor fluoxetine on glucose metabolism: A systematic review.. 2022 , 73, 103092	0
403	Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis.. 2022 ,	0
402	A rapid and sensitive LC-MS/MS method for determination of the active component K6 in serum of patients with depression.. 2022 , 213, 114691	
401	CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability.. 2022 , 312, 114535	0
400	Dose effects of tricyclic antidepressants in the treatment of acute depression - A systematic review and meta-analysis of randomized trials.. 2022 , 307, 191-198	0
399	Antidepressants for COVID-19: A systematic review.. 2022 ,	0
398	Mirtazapine treatment in a young female mouse model of Rett syndrome identifies time windows for the rescue of early phenotypes.. 2022 , 114056	
397	Treatment-resistant depression reconsidered. 2022 , 2, 100081	1
396	Agomelatine: An astounding sui-generis antidepressant?. 2021 ,	0
395	Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review.. 2021 , 1-18	2
394	Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach.. 2021 ,	0
393	Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop.. 2022 , 60, 7-12	2
392	Influence of functional gene polymorphisms on human behaviour: the case of .. 2021 , 46, E659-E662	

391	Degradation of Selected Antidepressants Sertraline and Citalopram in Ultrapure Water and Surface Water Using Gamma Radiation. 2022 , 10, 63	1
390	Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders.. 2021 , 11, 24226	0
389	Effects of escitalopram therapy on resting-state functional connectivity of subsystems of the default mode network in unmedicated patients with major depressive disorder.. 2021 , 11, 634	2
388	Differential potency of venlafaxine, paroxetine, and atomoxetine to inhibit serotonin and norepinephrine reuptake in patients with major depressive disorder.. 2021 ,	1
387	Depression and Anxiety Disorders. 305-450	
386	Prescribing in Older People. 601-677	1
385	Mirtazapine treatment in a young female mouse model of Rett syndrome identifies time windows for the rescue of early phenotypes during development.	
384	P.0394 Cognitive performance differences in patients with major depressive disorder treated with escitalopram, venlafaxine or vortioxetine. a 12-month follow-up. 2021 , 53, S283-S284	
383	Methylome-wide association study of antidepressant use in Generation Scotland and the Netherlands Twin Register implicates the innate immune system. 2021 ,	1
382	Método experimental e ensaios clínicos. 2021 , 52, e36259	1
381	Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research.. 2021 , 12, 792960	3
380	Efficacy of Sertraline Combined with Cognitive Behavioral Therapy for Adolescent Depression: A Systematic Review and Meta-Analysis.. 2021 , 2021, 5309588	2
379	P.0710 Exploring the rapidity of treatment effect for current treatment options for major depressive disorder. 2021 , 53, S519	
378	Modern Antidepressants in the Treatment of Mental Disorders in Post-COVID Conditions. 2021 , 692-698	
377	Assessing the hidden burden of psychiatric disease in patients with nonepileptic seizures. 2021 , 125, 108382	0
376	Boosting serotonin increases information gathering by reducing subjective cognitive costs.	0
375	Indirect prevention and treatment of depression: An emerging paradigm?. 2021 , 3,	2
374	Association of Task-Shared Psychological Interventions With Depression Outcomes in Low- and Middle-Income Countries: A Systematic Review and Individual Patient Data Meta-analysis.. 2022 ,	0

- 373 Erwartungseffekte beim Absetzen von Antidepressiva. **2022**, 67, 213 1
- 372 Revisiting the theoretical and methodological foundations of depression measurement. 10
- 371 Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.. **2022**, 2
- 370 Tolerability of duloxetine in elderly and in non-elderly adults: a protocol of a systematic review and individual participant data meta-analysis of randomized placebo-controlled trials.. **2022**, 11, 71
- 369 Acceptability, safety and tolerability of antidepressant repetitive transcranial magnetic stimulation for adolescents: A mixed-methods investigation.. **2022**,
- 368 Recommendations for the pharmacological treatment of treatment-resistant depression: A systematic review protocol.. **2022**, 17, e0267323 2
- 367 The association between antidepressant use and adherence to antihyperglycemic medications in adults with type 2 diabetes and depression: a retrospective cohort study. **2022**,
- 366 Antidepressant medication use by patients accessing a national digital mental health service.. **2022**, 308, 305-313 1
- 365 Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.. **2022**, 312, 114557
- 364 datasheet1.docx. **2020**,
- 363 image1.jpeg. **2020**,
- 362 image2.jpeg. **2020**,
- 361 Data_Sheet_1.docx. **2018**,
- 360 DataSheet_1.doc. **2020**,
- 359 DataSheet_1.pdf. **2020**,
- 358 DataSheet_2.pdf. **2020**,
- 357 DataSheet_1.docx. **2020**,
- 356 Table_1.docx. **2020**,

355 Table_2.docx. **2020**,

354 Data_Sheet_1.PDF. **2020**,

353 Table_1.docx. **2019**,

352 DataSheet_1.docx. **2020**,

351 Image_1.tiff. **2020**,

350 Image_2.tiff. **2020**,

349 Image_3.tiff. **2020**,

348 Data_Sheet_1.docx. **2019**,

347 Table_1.docx. **2019**,

346 Table_2.docx. **2019**,

345 Table_3.docx. **2019**,

344 Table_4.docx. **2019**,

343 Resistance training for Black men with depressive symptoms: a pilot randomized controlled trial to assess acceptability, feasibility, and preliminary efficacy.. **2022**, 22, 283

342 The Dose- and Duration-Dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta-Analysis of Randomized Placebo-Controlled Trials.. **2022**,

0

341 Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury. **2021**, 27, 152-224

2

340 Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive Disorders.. **2022**, 20, 248-258

339 Whole-Body Hyperthermia (WBH) in Psychiatry. **2022**, 155-164

338 Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study.. **2022**, 19, 268-280

0

- 337 Effects of pharmacological treatment on metabolomic alterations in animal models of depression.. **2022**, 12, 175 1
- 336 Antidepressants and Vertebral and Hip Risk Fracture: An Updated Systematic Review and Meta-Analysis. **2022**, 10, 803 0
- 335 Neurobiology of Depression: Chronic Stress Alters the Glutamatergic System in the Brain—Focusing on AMPA Receptor. **2022**, 10, 1005 0
- 334 Excess significance and power miscalculations in neurofeedback research.. **2022**, 103008 0
- 333 Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.. **2022**, 1-19 2
- 332 Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression? A systematic review and meta-analysis. **2022**, 0
- 331 Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis.. **2022**, 12, 183 0
- 330 Independent Replication and Drug-specificity of an Antidepressant Response Polygenic Risk Score. 0
- 329 Designing clinically useful psychopharmacological trials: challenges and ways forward.. **2022**, 2
- 328 Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review.. **2022**, 59, 68-81 1
- 327 Crocin ameliorates depressive-like behaviors induced by chronic restraint stress via the NAMPT-NAD-SIRT1 pathway in mice.. **2022**, 157, 105343 2
- 326 Lack of blinding in a cloud of unknowing: What remains of antidepressants' effectiveness?. **2022**, 313, 114609 0
- 325 Network Meta-Analysis. **2022**, 238-257 0
- 324 Dealing with Missing Outcome Data in Meta-Analysis. **2022**, 204-219 0
- 323 The efficacy of psilocybin in the treatment of depression and anxiety: A meta-analysis. **2022**, 18, 0
- 322 Pharmakotherapie depressiver Störungen. **2022**, 16, 229-250 0
- 321 Dietary Supplementations and Depression. Volume 15, 1121-1141 1
- 320 Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis.. **2022**, 5, e2212939 2

319	The intersection of astrocytes and the endocannabinoid system in the lateral habenula: on the fast-track to novel rapid-acting antidepressants.. 2022,	0
318	Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report.. 2022, 36, 604-613	0
317	Controversies In The Pharmacotherapy Of Adolescent Depression. 2022, 28,	
316	Association of Acupuncture and Auricular Acupressure With the Improvement of Sleep Disturbances in Cancer Survivors: A Systematic Review and Meta-Analysis. 2022, 12,	0
315	Understanding and managing psychological disorders in patients with inflammatory bowel disease: a practical guide. flgastro-2022-102094	0
314	The reduction of vitamin D in females with major depressive disorder is associated with worse cognition mediated by abnormal brain functional connectivity. 2022, 118, 110577	
313	Prospective associations of multimodal serum biomarkers with 12-week and 12-month remission in patients with depressive disorders receiving stepwise psychopharmacotherapy. 2022, 104, 65-73	0
312	The Impact of Mental Health Support for the Chronically Ill on Hospital Utilisation: Evidence from the UK.	
311	Accuracy of PHQ-9 Against Psychiatric Diagnosis for Depression Among People Living with HIV: A Mixed-Method Study in Cameroon, Kenya, and the Republic of Congo.	
310	Efficacy of the Integrative Acupuncture and Moxibustion Treatment in Patients With Major Depressive Disorder: The Study Protocol for a Multicenter, Single-Blinded, Randomized Trial in China. 2022, 9,	
309	Unraveling the Mysteries of Mental Illness With Psilocybin. 2022,	0
308	Linking GWAS to pharmacological treatments for psychiatric disorders.	
307	Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice. 026988112210930	
306	Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. 2022,	0
305	Edible Mushrooms as a Potential Component of Dietary Interventions for Major Depressive Disorder. 2022, 11, 1489	0
304	The Effect of Duloxetine on Mechanistic Pain Profiles, Cognitive Factors, and Clinical Pain in Patients with Painful Knee Osteoarthritis – A Randomized, Double-Blind , Placebo-Controlled , Crossover Study.	1
303	Symptomatic versus disease-modifying effects of psychiatric drugs.	0
302	Comparative efficacy and acceptability of drug treatments for Parkinson’s disease with depression: A systematic review with network meta-analysis. 2022, 175070	1

301	Acupuncture Ameliorates Depressive Behaviors by Modulating the Expression of Hippocampal Iba-1 and HMGB1 in Rats Exposed to Chronic Restraint Stress. 2022 , 13,	0
300	How do income changes impact on mental health and wellbeing for working-age adults? A systematic review and meta-analysis. 2022 , 7, e515-e528	2
299	Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package. 2022 , 17, e0268754	0
298	The Hierarchical Taxonomy of Psychopathology (HiTOP) in psychiatric practice and research. 1-13	2
297	Anatomy of a Woebot™ (WB001): agent guided CBT for women with postpartum depression. 2022 , 19, 287-301	0
296	Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: a systematic review and dose-effect meta-analysis.	
295	Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia.	2
294	Single-cell activity and network properties of dorsal raphe nucleus serotonin neurons during emotionally salient behaviors. 2022 ,	1
293	Care pathways for people with major depressive disorder: a European Brain Council Value of Treatment study. 1-21	1
292	Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice. Volume 18, 1175-1193	0
291	Prevalence and associated factors with Traditional, Complementary and Integrative Medicine in Brazil: a population-based study. 2022 , 102146	
290	Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis.	1
289	The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. Volume 18, 1133-1143	1
288	The importance of evidence synthesis in psychopharmacology: Insights from a scientometric approach. 2022 , 61, 30-32	
287	Comparative Efficacy and Tolerability of Nutraceuticals for Depressive Disorder: A Systemic Review and Network Meta-Analysis.	
286	Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. 2022 , 12, 204512532211051	1
285	Recovery-Oriented Treatments in Major Depressive Disorder. 2022 , 245-254	
284	Addressing fatigue in inflammatory rheumatic diseases. 2022 ,	

283	Recent advances in the development of antidepressants targeting the purinergic P2X7 receptor. 2022 , 29,	0
282	The pharmacogenomics of selective serotonin reuptake inhibitors.	2
281	Combination Antidepressant Therapy vs MonotherapyâFurther ConsiderationsâReply.	
280	The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.	1
279	Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age. 13,	0
278	Clinical, demographic, and genetic risk factors of treatment-attributed suicidality in >10,000 Australian adults taking antidepressants.	
277	Development of a model to predict antidepressant treatment response for depression among Veterans. 1-11	0
276	The effect of vitamin D supplementation on depressive symptoms in adults: A systematic review and meta-analysis of randomized controlled trials. 1-18	2
275	Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial. 2022 , 12,	1
274	Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. <i>Lancet, The</i> , 2022 , 400, 170-184	6
273	Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response. 2022 , 12, 940	0
272	Alterations of Plasma Lipids in Adult Women With Major Depressive Disorder and Bipolar Depression. 13,	
271	Identification of Sex-Specific Plasma Biomarkers Using Metabolomics for Major Depressive Disorder in Children and Adolescents. 13,	0
270	Insomnia: Large study shows how well different drugs work. o1758	
269	Reliability of Evidence to Guide Decision-Making in the Use of Acupuncture for Postpartum Depression. 10,	
268	Electrochemical Behavior of Duloxetine Hydrochloride at Au and GC Solid Electrodes: Its Quantitative Determination and Degradation. 2022 , 169, 076507	
267	Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000â2020: A systematic review and meta-analysis. 2022 , 50, 101505	0
266	Risk factors and consequences of traumatic brain injury in a Swiss male population cohort. 2022 , 12, e055986	2

- 265 Gut microbiome: A potential indicator for predicting treatment outcomes in major depressive disorder. 16, 1
- 264 From living systematic reviews to meta-analytical research domains. ebmental-2022-300509 0
- 263 Feasibility, engagement, and preliminary clinical outcomes of a digital biodata-driven intervention for anxiety and depression. 4,
- 262 Comment to "Requiem or resurrection: Classic monoamine oxidase inhibitors revisited" 2022, 62, 61-62
- 261 What Can Reinforcement Learning Models of Dopamine and Serotonin Tell Us about the Action of Antidepressants?. 2022, 6, 166-188 0
- 260 Important adverse events to be evaluated in antidepressant trials and meta-analyses in depression: a large international preference study including patients and healthcare professionals. ebmental-2021-300418⁰
- 259 Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. 026988112211040 0
- 258 Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine. 2022, 239, 2735-2752 2
- 257 Efficacy of a novel proprietary dietary supplement (TRI 360™) on psychological symptoms and stress-related quality of life in adult subjects: A randomized controlled clinical trial. 13, 0
- 256 Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder. 2022,
- 255 High-order brain functional network for electroencephalography-based diagnosis of major depressive disorder. 16, 0
- 254 Statins in depression: a repurposed medical treatment can provide novel insights in mental health. 1-16 2
- 253 Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. 1-8
- 252 An assessor-blinded, randomized comparative trial of transcutaneous auricular vagus nerve stimulation (taVNS) combined with cranial electroacupuncture vs. citalopram for depression with chronic pain. 13, 0
- 251 Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms. 026988112211183
- 250 Pharmacological interventions for depression in adults with chronic hepatitis B or C. 2022, 2022,
- 249 Antidepressant Effect of Neuropeptide Y in Models of Acute and Chronic Stress. 2022, 90, 50 0
- 248 Treatment of adjustment disorders in mental health crisis care: a reflective case study. 2022, 11, 1-10

247	BDNF-related mutations in major depressive disorder: a systematic review. 1-61	0
246	NEUROTRANSMITTER TRANSPORTER/RECEPTOR CO-EXPRESSION SHARES ORGANIZATIONAL TRAITS WITH BRAIN STRUCTURE AND FUNCTION.	0
245	Experiences of treatment-resistant mental health conditions in primary care: a systematic review and thematic synthesis. 2022 , 23,	0
244	The rationale and guiding principles to design a psychiatry curriculum for primary care doctors of India. 35, 32-37	
243	Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. e067606	3
242	Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.	1
241	Effectiveness of acupuncture in postpartum depression: A protocol for an overview of systematic reviews. 2022 , 101, e28678	
240	The Cannabis-Induced Epigenetic Regulation of Genes Associated with Major Depressive Disorder. 2022 , 13, 1435	0
239	Antidepressants and the serotonin hypothesis of depression. o1993	0
238	Adherence to antidepressant therapy: clinical experience on the example of agomelatine. 2022 , 14, 82-86	
237	Antidepressant use and risk of self-harm among people aged 40 years or older: A population-based cohort and self-controlled case series study. 2022 , 27, 100557	0
236	Comparative efficacy and acceptability of psychotherapies, pharmacotherapies, and their combination for the treatment of adult insomnia: A systematic review and network meta-analysis. 2022 , 65, 101687	0
235	Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies. 2022 , 316, 201-208	1
234	Trends in U.S. Depression Prevalence From 2015 to 2020: The Widening Treatment Gap. 2022 ,	2
233	Serum amyloid P component (SAP) modulates antidepressant effects through promoting membrane insertion of the serotonin transporter.	0
232	Emerging drugs for the treatment of major depressive disorder. 1-13	0
231	Physical exercise prevents behavioral alterations in a reserpine-treated zebrafish: A putative depression model. 2022 , 220, 173455	0
230	The role of reelin in the pathological mechanism of depression from clinical to rodents. 2022 , 317, 114838	0

- 229 Understanding treatment-resistant depression using omics techniques: A systematic review. **2022**, 318, 423-455 ○
- 228 Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease. **2023**, 18, 727 1
- 227 Depressive episode. **2022**, 45-60 ○
- 226 Alternative Ligands at Melatonin Receptors. **2022**, 151-162 ○
- 225 Nutrition and Psychiatric Disorders: Focus on Schizophrenia. **2022**, 313-368 ○
- 224 Prescribing Antidepressant Medication. **2022**, 17-34 ○
- 223 EEG Biomarkers to Predict Response to Sertraline and Placebo Treatment in Major Depressive Disorder. **2022**, 1-11 ○
- 222 Mental health in adults with 22q11.2 deletion syndrome. **2022**, 322-337 ○
- 221 Stress and the Gut-Brain Axis. **2022**, 7, 137-146 ○
- 220 A guide to prescribing antidepressants in primary care. **2022**, 33, 11-18 ○
- 219 Integrative multi-omics landscape of fluoxetine action across 27 brain regions reveals global increase in energy metabolism and region-specific chromatin remodelling. ○
- 218 Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis. **2022**, 1 1
- 217 Multicriteria Decision-Making Methods for Optimal Treatment Selection in Network Meta-Analysis. 0272989X20211266 ○
- 216 Motivating young adults to connect with nature for stress relief: A study in Taiwan during the COVID-19 pandemic. 13, ○
- 215 A Mutually Reinforcing System? Longitudinal Changes in Psychological Distress, Functional Impairment, and Prescription Medication Consumption Among Adults. **2022**, 24, 112-123 ○
- 214 Comparative effectiveness of exercise, antidepressants and their combination in treating non-severe depression: a systematic review and network meta-analysis of randomised controlled trials. bjsports-2022-105964 ○
- 213 Individualized fMRI connectivity defines signatures of antidepressant and placebo responses in major depression. ○
- 212 Combined repetitive transcranial magnetic stimulation and medication treatment for depression is associated with serum amyloid a level: Evidence from naturalistic clinical practice. 16, ○

211	Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.	0
210	5-HTR2B and SLC6A3 as potential molecular targets of sertraline in the treatment of major depressive disorder: the use of bioinformatics and its practical implication. 2022 , 11,	0
209	Introducing a depression-like syndrome for translational neuropsychiatry: a plea for taxonomical validity and improved comparability between humans and mice.	1
208	Olfactory loss is a predisposing factor for depression, while olfactory enrichment is an effective treatment for depression. 16,	0
207	Antidepressant use and risk of adverse outcomes: population-based cohort study. 2022 , 8,	0
206	Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. 2022 , 8,	1
205	Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study. 2022 , 12,	0
204	Neferine alleviates chronic stress-induced depression by regulating monoamine neurotransmitter secretion and gut microbiota structure. 13,	0
203	Trends in the utilization of psychotropic medications in China from 2018 to 2021. 13,	1
202	Neural mechanism of the relationship between sleep efficiency and clinical improvement in major depressive disorder: A longitudinal functional magnetic resonance imaging study. 13,	0
201	3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. 13,	0
200	Is depression the missing link between inflammatory mediators and cancer?. 2022 , 108293	0
199	Praktische Aspekte der antidepressiven Pharmakotherapie. 2022 , 23, 64-71	0
198	A functional population-specific variant rs77416373 in the CaV2.1 gene is associated with antidepressant treatment response in Han Chinese subjects with major depressive disorder. 2022 , 77, 103272	0
197	Electrical stimulus combined with venlafaxine and mirtazapine improves brain Ca ²⁺ activity, pre-pulse inhibition, and immobility time in a model of major depressive disorder in schizophrenia. 2022 , 319, 610-617	0
196	Effectiveness of CBT and its modifications for prevention of relapse/recurrence in depression: A systematic review and meta-analysis of randomized controlled trials. 2022 , 319, 469-481	0
195	Cognitive Behavioral Therapy. 2022 , 291-300	0
194	Post-traumatic stress disorder in the focus of international research: from soldier heart to ICD-11. 2022 , 122, 72	2

- 193 Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19. **2022**, 11, 5882 1
- 192 Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis. 0
- 191 Polygenic heterogeneity in antidepressant treatment and placebo response. **2022**, 12, 0
- 190 Tryptophan-5-HT pathway disorder was uncovered in the olfactory bulb of a depression mice model by metabolomic analysis. 15, 0
- 189 Project Rebuild the Evidence Base (REB): a method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients. **2022**, 0
- 188 Transcriptional signatures of the cortical morphometric similarity network gradient in first-episode, treatment-naïve major depressive disorder. 0
- 187 Pharmacogenomics in treatment of depression and psychosis: an update. **2022**, 1
- 186 The use of antidepressants is linked to bone loss: A systematic review and metanalysis. **2022**, 14, 0
- 185 Study protocol for âMDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle studyâ13, 0
- 184 Therapeutic potential of plant iridoids in depression: a review. **2022**, 60, 2167-2181 0
- 183 Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. 2
- 182 An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression. 025371762211271 0
- 181 Interactive Effects of Serum Leptin Levels and Physical Comorbidity on the Pharmacotherapeutic Response of Depressive Disorders. **2022**, 20, 662-674 0
- 180 G protein-biased LPAR1 agonism promotes prototypic antidepressant effects. 0
- 179 Comparative efficacy and safety of antiviral traditional Chinese medicine injections for viral pneumonia: a systematic review and network meta-analysis. 0
- 178 Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: A network meta-analysis of randomized controlled trials. **2022**, 88, 101196 0
- 177 Psilocybin in Treatment-Resistant Depression. **2022**, 387, 1708-1709 1
- 176 Botulinum Toxin in Facial Aesthetics Affects the Emotion Process: A Meta-analysis of Randomized Controlled Trials. **2022**, 20, 600-608 1

- 175 Can Fluoxetine Combined with Cognitive Behavioral Therapy Reduce the Suicide and Non-Suicidal Self-Injury Incidence and Recurrence Rate in Depressed Adolescents Compared with Fluoxetine Alone? A Meta-Analysis. Volume 18, 2543-2557 ○
- 174 Efficacy of nondrug interventions in perinatal depression: A meta-analysis. **2022**, 317, 114916 ○
- 173 Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders. **2022**, 156, 390-397 ○
- 172 Partly recovery and compensation in anterior cingulate cortex after SSRI treatment—evidence from multi-voxel pattern analysis over resting state fMRI in depression. **2023**, 320, 404-412 ○
- 171 Pharmakotherapie: Allgemeine Aspekte. **2023**, 143-147 ○
- 170 Pharmakotherapie: Akuttherapie. **2023**, 149-164 ○
- 169 Trazodone and Depression. **2022**, 1247-1255 ○
- 168 Antidepressants: Indications, Contraindications, Interactions, and Side Effects. **2022**, 1135-1172 ○
- 167 Amitriptyline and Depressions. **2022**, 1205-1223 ○
- 166 Effects of Psychopharmacological Medicines upon Driving Ability. **2022**, 4339-4353 ○
- 165 Serotonin Reuptake Inhibitors: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline. **2022**, 1257-1269 ○
- 164 Bupropion and Depressions. **2022**, 1271-1280 ○
- 163 Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. **2022**, 1173-1191 ○
- 162 Randomized Controlled Trials and the Efficacy of Psychotropic Medications. **2022**, 305-359 ○
- 161 Mirtazapine and Depressions. **2022**, 1281-1309 ○
- 160 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran. **2022**, 1319-1345 ○
- 159 Combination Therapies and Switching of Agents in Depression and Bipolar Disorders. **2022**, 4479-4495 ○
- 158 Psychopharmacotherapy of Depressive Disorders. **2022**, 4033-4073 ○

157	Agomelatine and Depressions. 2022 , 1381-1391	0
156	Psychopharmacology: A Brief Overview of Its History. 2022 , 621-660	0
155	Guidelines for the Use of Parkinsonian Drugs in Canada. 2022 , 3015-3023	0
154	Meta-Analysis of Antidepressant Pharmacotherapy in Patients Eligible for Cardiac Rehabilitation. 2022 , 42, 434-441	0
153	The serotonin theory of depression and why we use antidepressants. 2022 , 72, 536-537	0
152	Gender-Affirming Treatment of Gender Dysphoria in Youth: A Perfect Storm Environment for the Placebo Effect—The Implications for Research and Clinical Practice.	2
151	Biomarker opportunities in the treatment of cancer-related depression. 2022 ,	0
150	Combining Transcranial Magnetic Stimulation with Antidepressants: A Systematic Review and Meta-Analysis.	0
149	Different depression: motivational anhedonia governs antidepressant efficacy in Huntington's disease.	1
148	Transcriptomic Studies of Antidepressant Action in Rodent Models of Depression: A First Meta-Analysis. 2022 , 23, 13543	1
147	Mood Variability Craving and Substance Use Disorders: From Intrinsic Brain Network Connectivity to Daily Life Experience. 2022 ,	0
146	Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model. 2022 , 23, 13623	0
145	A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. 13,	0
144	Chronic Trazodone and Citalopram Treatments Increase Trophic Factor and Circadian Rhythm Gene Expression in Rat Brain Regions Relevant for Antidepressant Efficacy. 2022 , 23, 14041	0
143	In Vivo Antidepressant-Like Effect Assessment of Two Aloysia Species in Mice and LCMS Chemical Characterization of Ethanol Extract. 2022 , 27, 7828	1
142	Effective management of depression among patients with cancer (ENHANCE): a protocol for a hybrid systematic review and network meta-analysis of randomised controlled trials of interventions for depressive symptoms. 2022 , 11,	0
141	Use of central nervous system drugs in combination with selective serotonin reuptake inhibitor treatment: A Bayesian screening study for risk of suicidal behavior. 13,	0
140	Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis. 13,	1

- 139 Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers. **2022**, 44, 720-728 ○
- 138 S-adenosyl-l-methionine antidepressant-like effects involve activation of 5-HT1A receptors. **2022**, 105442 ○
- 137 Patient characteristics associated with retrospectively self-reported treatment outcomes following psychological therapy for anxiety or depressive disorders - a cohort of GLAD study participants. **2022**, 22, ○
- 136 The effectiveness of off-label dopamine stimulating agents in depressive disorder: A systematic review and meta-analysis. **2023**, 319, 115010 ○
- 135 New goals for depression therapy. **2022**, 122, 57 ○
- 134 Diagnostic value of MicroRNAs for depression: A systematic review and meta-analysis. **2023**, 157, 132-140 ○
- 133 Predicting the efficacy of escitalopram in the treatment of depression through urinary proteome. **2023**, 484, 116980 ○
- 132 Effect of sleep deprivation plus existing therapies on depression: A systematic review and meta-analysis of randomized controlled trials. **2023**, 184, 1-11 ○
- 131 Effects of neuronavigation-guided rTMS on serum BDNF, TrkB and VGF levels in depressive patients with suicidal ideation. **2023**, 323, 617-623 ○
- 130 Trends in sales of antidepressants in Brazil from 2014 to 2020: A time trend analysis with joinpoint regression. **2023**, 323, 213-218 ○
- 129 Comparative efficacy, acceptability, and tolerability of adjunctive anti-inflammatory agents on bipolar disorder: A systemic review and network meta-analysis. **2023**, 80, 103394 ○
- 128 Le patient souffrant de pathologies psychiatriques chroniques ou r currentes pr valentes. **2022**, 187-201 ○
- 127 UPLC Technique in Pharmacy  n Important Tool of the Modern Analyst. **2022**, 10, 2498 1
- 126 Integrated Module of Multidimensional Omics for Peripheral Biomarkers (iMORE) in patients with major depressive disorder: rationale and design of a prospective multicentre cohort study. **2022**, 12, e067447 ○
- 125 Internet Use, Social Participation, and Depressive Symptoms Among Middle-aged and Elderly Chinese: Empirical Study Based on Secondary Data (Preprint). ○
- 124 Determining Current Medications Usage within a Cohort of Patients in the UK   Descriptive Retrospective Study. **2022**, 10, 2421 ○
- 123 Interventions for Adult Depression in Primary Health-Care Clinics. **2023**, 123-140 ○
- 122 A vueltas con la hip tesis bioqu mica de la depresi n: Bilis negra y serotonina. **2022**, 13, ○

- 121 Systematic review and network meta-analysis of different types of emollient for the prevention of atopic dermatitis in infants. 0
- 120 Gut microbiome-wide association study of depressive symptoms. **2022**, 13, 6
- 119 Economic burden of depression in Brazil: a cost-of-illness study based on productivity losses and healthcare costs between 2010 to 2018. 1-9 0
- 118 Images of depression in Charles Baudelaire: clinical understanding in the context of poetry and social history. 1-5 0
- 117 Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. 0
- 116 Comparative efficacy, cognitive effects and acceptability of electroconvulsive therapies for the treatment of depression: protocol for a systematic review and network meta-analysis. **2022**, 12, e068313 1
- 115 Berücksichtigung von Komorbiditäten in der Wirksamkeitsforschung zu Depressionsbehandlungen – ein narratives Review. 0
- 114 Pre-frontal stimulation does not reliably increase reward responsiveness. **2022**, 0
- 113 Neural correlates of psychodynamic and non-psychodynamic therapies in different clinical populations through fMRI: A meta-analysis and systematic review. 16, 0
- 112 The long noncoding RNA FEDORA is a cell type- and sex-specific regulator of depression. **2022**, 8, 0
- 111 Using filled prescription sequences to rank antidepressants: A nationwide replication study. **2022**, 0
- 110 Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. **2022**, 1, e000017 0
- 109 Antidepressanların Kullanımı ve Etkili Faktörler: Türkiye ve Almanya Karşılaştırması. 0
- 108 Novel and emerging treatments for major depression. **2022**, 2
- 107 Praktische Aspekte der antidepressiven Pharmakotherapie. **2022**, 19, 21-29 0
- 106 Depression in Women With Inflammatory Bowel Disease: A Multifaceted Approach for a Multidimensional Problem. 0
- 105 HIPNOSE: definição, importância, limitações e possibilidades baseadas em evidências. **2022**, 8, 226-245 0
- 104 Neurobiological reduction: From cellular explanations of behavior to interventions. 13, 0

103	Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.	0
102	Systematic review of Kaixinsan in treating depression: Efficacy and pharmacological mechanisms. 16,	0
101	Optimal parameter determination of repetitive transcranial magnetic stimulation for treating treatment-resistant depression: A network meta-analysis of randomized controlled trials. 13,	0
100	Assessment of clinical outcomes of medicinal cannabis therapy for depression: Analysis from the UK Medical Cannabis Registry.	2
99	Psychiatrische Autoimmunenkephalitis â Diagnose und therapeutische Anze. 2023 , 17, 13-28	0
98	Trajectories of depression symptoms in a therapist-supported digital mental health intervention: a repeated measures latent profile analysis.	0
97	TEDâTrazodone Efficacy in Depression: A Naturalistic Study on the Efficacy of Trazodone in an Extended-Release Formulation Compared to SSRIs in Patients with a Depressive EpisodeâPreliminary Report. 2023 , 13, 86	0
96	Pharmacogenetics of anxiety and depression in Alzheimer's disease.	0
95	The potential of vortioxetine in treating obsessive-compulsive disorder. 2023 , 103460	0
94	Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis. 2023 , 101746	0
93	Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis. 13,	0
92	Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance. 1-14	0
91	Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. 2023 , 109418	0
90	Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. 2023 , 22, 105-115	1
89	The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. 2023 , 22, 48-74	7
88	Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses. Volume 19, 1-25	0
87	Transdiagnostic treatment of depression and anxiety: a meta-analysis. 1-12	1
86	Synthesizing cross-design evidence and cross-format data using network meta-regression.	0

- 85 Risk of depressive disorders associated with medical cannabis authorization: A propensity score matched cohort study. **2023**, 320, 115047 ○
- 84 Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States. **2022**, 28, S2-S13 ○
- 83 Effects of Urban Forest Therapy Program on Depression Patients. **2023**, 20, 507 ○
- 82 Novel Antidepressant Mechanism of Ginsenoside Rg1 in Regulating the Dysfunction of the Glutamatergic System in Astrocytes. **2023**, 24, 575 ○
- 81 Does Bupropion Increase Anxiety?. Publish Ahead of Print, ○
- 80 The beneficial effect on cognition of noninvasive brain stimulation intervention in patients with dementia: a network meta-analysis of randomized controlled trials. **2023**, 15, ○
- 79 Psychological treatment of depression with other comorbid mental disorders: systematic review and meta-analysis. 1-23 ○
- 78 Nanoparticulate MgH₂ ameliorates anxiety/depression-like behaviors in a mouse model of multiple sclerosis by regulating microglial polarization and oxidative stress. **2023**, 20, ○
- 77 SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants. ○
- 76 Trends, Patterns and Associated User Characteristics of Antidepressant Prescriptions in Older Adults: A Nationwide Descriptive Cohort Study in Denmark. ○
- 75 Investigating the potential anti-depressive mechanisms of statins: a transcriptomic and Mendelian randomization analysis. **2023**, 13, ○
- 74 Comparative efficacy and acceptability of non-pharmacological interventions for depression in people living with HIV: A systematic review and network meta-analysis. **2023**, 140, 104452 ○
- 73 Molecular Characterization and Pharmacology of Melatonin Receptors in Animals. **2023**, 2, 127-147 ○
- 72 Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR). **2023**, 161, 132-139 ○
- 71 Concurrent use of polypharmacy and potentially inappropriate medications with antidepressants in older adults: A nationwide descriptive study in Denmark during 2015-2019. **2023**, 82, 66-74 ○
- 70 Nonresponder does not mean not better: Improvement in nonsymptom domains in complex depressed patients who are not symptomatic responders to intensive treatment. **2023**, 323, 115162 ○
- 69 Unblinding and demand characteristics in the treatment of depression. **2023**, 328, 1-5 ○
- 68 Management of depression in patients with coronary artery disease: A systematic review. **2023**, 83, 103534 ○

- 67 A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. **2023**, 329, 72-80 ○
- 66 Bridging rapid and sustained antidepressant effects of ketamine. **2023**, 29, 364-375 ○
- 65 Ganoderma lucidum ethanol extract promotes weight loss and improves depressive-like behaviors in male and female Swiss mice. **2023**, 265, 114155 ○
- 64 Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder. **2023**, 332, 105-114 ○
- 63 Prevalence of depression and anxiety in older people in low- and middle- income countries in Africa, Asia and South America: A systematic review and meta-analysis. **2023**, 325, 656-674 ○
- 62 PALM: Patient-centered treatment ranking via large-scale multivariate network meta-analysis. **2023**, 17, ○
- 61 Development of a model to predict combined antidepressant medication and psychotherapy treatment response for depression among veterans. **2023**, 326, 111-119 ○
- 60 Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial. **2023**, 21, 135-146 ○
- 59 The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder. **2023**, 159, 266-273 1
- 58 The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD): Changes in Preferred Treatment Strategies and Medications over 20 Years and Five Editions. **2023**, 12, 1146 ○
- 57 Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom. **2022**, 451-495 ○
- 56 Individualized fMRI connectivity defines signatures of antidepressant and placebo responses in major depression. ○
- 55 Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine. 14, ○
- 54 Antidepressant treatment initiation and public sick-leave compensation in the following year: a register-based prospective cohort study in Denmark. 1-9 ○
- 53 Guidelines recommendations for the treatment-resistant depression: A systematic review of their quality. **2023**, 18, e0281501 ○
- 52 Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. **2023**, 327, 120-127 ○
- 51 Understanding mental health through computers: An introduction to computational psychiatry. 14, ○
- 50 Effects of 12-week escitalopram treatment on resting-state functional connectivity of large-scale brain networks in major depressive disorder. **2023**, 44, 2572-2584 ○

- 49 Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders. **2023**, 13, 318 ○
- 48 Interventions to Reduce Parental Substance Use, Domestic Violence and Mental Health Problems, and Their Impacts Upon Children's Well-Being: A Systematic Review of Reviews and Evidence Mapping. 152483802311538 ○
- 47 The Effectiveness of a Mobile-Based Physical Activity Program for Treating Depression Among Adults in Korea: A Pilot Study (Preprint). ○
- 46 Organic cation transporter 2 contributes to SSRI antidepressant efficacy by controlling tryptophan availability in the brain. ○
- 45 Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists. **2023**, 13, 333 ○
- 44 Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression. **2023**, 6, e230147 ○
- 43 Is the serotonin hypothesis/theory of depression still relevant? Methodological reflections motivated by a recently published umbrella review. **2023**, 273, 1-3 ○
- 42 The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses. 14, ○
- 41 Antidepressiva – State of the Art. **2023**, 56, 100-106 ○
- 40 Lower sertraline plasma concentration in patients co-medicated with clozapine – Implications for pharmacological augmentation strategies in schizophrenia. **2023**, 11, ○
- 39 Acute toxicity and genotoxicity studies on new melatonergic antidepressant GW117. **2023**, 9, e14026 ○
- 38 Therapieresistenz unipolarer depressiver Erkrankung: Definition, Häufigkeit, Charakteristika, Prädiktoren und Risikofaktoren. **2022**, 3-32 ○
- 37 Genetic and physiological factors predisposing to individual selective serotonin reuptake inhibitors exposure during pregnancy and breast feeding. **2023**, 6-14 ○
- 36 Depression and Its Phytopharmacotherapy – Narrative Review. **2023**, 24, 4772 ○
- 35 Treatment Response Following Adaptive PASAT Training for Depression Vulnerability: a Systematic Review and Meta-Analysis. ○
- 34 Impact of Sertraline, Fluoxetine, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder. **2023**, 11, 740 ○
- 33 Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. ○
- 32 Early prenatal and late prenatal escitalopram exposure differentially impacts behavioral flexibility and anxiety-related behaviors in adulthood. **2023**, 224, 173534 ○

- 31 Interactions Between Antidepressants and Intestinal Microbiota. **2023**, 20, 359-371
- 30 Deep phenotyping towards precision psychiatry of first-episode depression in the Brain Drugs-Depression cohort. **2023**, 23,
- 29 Treatment of adjustment disorders in mental health crisis care: a reflective case study. **2023**, 5, 122-128
- 28 Next generation antidepressants with novel mechanisms for treatment resistant depression. **2023**,
- 27 Efficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyond. **2023**, 15,
- 26 Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression. 1-17
- 25 Affective Disorders Using the Example of Unipolar Depression. **2023**, 283-310
- 24 Rethinking the medication management of major depression. **2023**, 23, 331-363
- 23 Interventions to help patients withdraw from depression drugs: systematic review.
- 22 Fifty years on: Serotonin and depression. **2023**, 37, 237-241
- 21 Exploring the Potential of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 as Promising Psychobiotics Using SHIME. **2023**, 15, 1521
- 20 Adjunctive transcranial alternating current stimulation for patients with major depressive disorder: A systematic review and meta-analysis. 14,
- 19 THERAPY OF POST-COVID DEPRESSION: A PROACTIVE PSYCHOSOMATIC APPROACH. **2023**, 51, 5-13
- 18 Depressionen bei Diabetes mellitus (Teil 2).
- 17 Deprescribing psychotropic medicines for behaviours that challenge in people with intellectual disabilities: a systematic review. **2023**, 23,
- 16 The risks of adverse events with venlafaxine and mirtazapine versus active placebo, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. **2023**, 12,
- 15 Factors associated with higher quality of clinical practice guidelines and their recommendations for the pharmacological treatment of depression: a systematic review. **2023**, 13, e067390
- 14 Click chemistry inspired syntheses of new amide linked 1,2,3-triazoles from naphthols: biological evaluation and in silico computational study.

13	Non-opioid analgesics for the prevention of chronic postsurgical pain: a systematic review and network meta-analysis. 2023 ,	0
12	Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report Data. 2023 ,	0
11	Journeying Through Different Mythic Worlds. 2023 , 12, 96-111	1
10	Antidepressants amitriptyline, fluoxetine, and traditional Chinese medicine Xiaoyaosan caused alterations in gut DNA virome composition and function in rats exposed chronic unpredictable mild stress. 14,	0
9	Sickness Behaviour and Depression: An Updated Model of Peripheral-Central Immunity Interactions. 2023 ,	0
8	Probiotics for the treatment of depression and its comorbidities: A systemic review. 13,	0
7	Web Search Query Volume Correlates With Prescription Volumes of Antidepressants and Antipsychotics in the Netherlands and United Kingdom. Publish Ahead of Print,	0
6	Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis. 2023 , 13, 1043	0
5	Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder. 14,	0
4	Impact of Diagnosis-Related Groups on Inpatient Quality of Health Care: A Systematic Review and Meta-Analysis. 2023 , 60, 004695802311670	0
3	Antidepressant pharmaceuticals in aquatic systems, individual-level ecotoxicological effects: growth, survival and behavior. 2023 , 260, 106554	0
2	The diagnosis and treatment of unipolar depressionâNational Disease Management Guideline.	0
1	Catalogue of bias: novelty bias. bmjebm-2022-112215	0